




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 311/54, A61K 31/64	A1	(11) International Publication Number: WO 98/32733 (43) International Publication Date: 30 July 1998 (30.07.98)
(21) International Application Number: PCT/IB97/01603 (22) International Filing Date: 29 December 1997 (29.12.97) (30) Priority Data: 60/036,979 29 January 1997 (29.01.97) US (71) Applicant (for all designated States except US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DOMBROSKI, Mark, Anthony [US/US]; 36 Stoneheights Drive, Waterford, CT 06385 (US). EGGLER, James, Frederick [US/US]; 184 Elm Street, Stonington, CT 06378 (US). (74) Agents: SPIEGEL, Allen, J. et al.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY (57) Abstract <p>A compound of formula (I) wherein R¹ and R² are as defined in the description, R² being an aromatic group, useful in the treatment and condition selected from the group consisting of the group meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzheimer's disease, percussion injury, depression, atherosclerosis, osteoporosis in a mammal, including a human.</p> <div style="text-align: right; margin-top: 20px;">  <p style="text-align: center;">(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

SULFONYL UREA DERIVATIVES AND THEIR USE IN THE
CONTROL OF INTERLEUKIN-1 ACTIVITY

Background of the Invention

This invention relates to substituted urea derivatives useful in the treatment of inflammation in joints, central nervous system, gastrointestinal tract, endocardium, pericardium, lung, eyes, ears, skin and urogenital system. More particularly, this invention relates to aryl and heteroaryl substituted sulfonyl ureas that are useful inhibitors of interleukin-1 α and interleukin-1 β processing and release.

IL-1's status as an important mediator of inflammation is based on many studies demonstrating this cytokine's proinflammatory activity. In vivo these effects are manifest as stimulation of cartilage resorption, induction of leukocyte recruitment and the acute phase response, and the production of fever and a shock like state. The changes mediated by IL-1 binding to its receptor include regulation of adhesion molecules and chemokines, stimulation of metalloprotease synthesis, increased synthesis of cyclooxygenase-2 and phospholipase A2 thus increasing prostaglandin production, the induction of nitric oxide synthase thus increasing nitric oxide production and stimulation of IL-6 synthesis resulting in changes in the synthesis of acute phase proteins. Two distinct forms of IL-1 (IL-1 α and IL-1 β) are produced by monocytes and macrophages in response to inflammatory stimuli.

The initial translation product of human IL-1 β is a 31 kDa polypeptide that is incompetent to bind to IL-1 receptors on target cells. To promote its biological activity, proIL-1 β first must be cleaved by a thiol protease to generate a 17 kDa mature polypeptide species. This protease, interleukin-1 convertase (ICE), is a member of a novel family of cytosolic proteases that require an aspartic acid residue at the P1 subsite of their substrates. In contrast to proIL-1 β , 31 kDa proIL-1 α is competent to bind to IL-1 receptors; nonetheless, this cytokine also is processed to a 17 kDa species by a protease distinct from ICE.

Both forms of IL-1 are synthesized without signal sequences and, as a result, these cytokines accumulate within the cytoplasm of LPS activated monocytes and macrophages. Thus, unlike the majority of secreted cytokines that are processed via the traditional secretory apparatus of the cell involving the endoplasmic reticulum and Golgi apparatus, IL-1 must gain access to the extracellular compartment via a novel secretory pathway. The mechanistic elements of this pathway remain unknown. Recent studies, however, have demonstrated that synthesis of IL-1 β is not coupled to

-2-

its secretion. Agents that serve as a stimulus to promote IL-1 β posttranslational processing (both proteolytic cleavage by ICE and release of the mature 17 kDa species) include ATP, cytolytic T-cells, and ionophores such as nigericin. Importantly, LPS-activated murine peritoneal macrophages in vivo also require a secondary stimulus to promote efficient release of mature IL-1 β , and ATP was demonstrated to serve in this capacity. Thus, IL-1 β production is highly regulated both in vitro and in vivo by requiring separate stimuli to promote transcription, translation, and posttranslational maturation/release.

Therapeutic approaches that seek to inhibit ICE as a means to regulate production of IL-1 are likely to be limited because ICE inhibitors: 1) do not block release of proIL-1 β which could be processed extracellularly by other proteases to generate a mature biologically active cytokine species, and 2) do not decrease production of IL-1 α by activated monocytes/macrophages. Therefore, a therapeutic approach that prevents activation of the posttranslational processing and release of IL-1 is likely to provide efficacy superior to that of an ICE inhibitor by blocking externalization of both cytokine species.

Mammalian cells capable of producing IL-1 include, but are not limited to, keratinocytes, endothelial cells, mesangial cells, thymic epithelial cells, dermal fibroblasts, chondrocytes, astrocytes, glioma cells, mononuclear phagocytes, granulocytes, T and B lymphocytes and NK cells.

The activities of interleukin-1 are many. Subcutaneous injection of IL-1 leads to fever, sleepiness, anorexia, generalized myalgias, arthralgias, headache, and, on increasing exposure, hypotension. Margination of neutrophils and maximal extravascular infiltration of the polymorphonuclear leukocytes (PMN) is also observed. IL-1 also stimulates chondrocytes to release matrix metalloproteases, resulting in the degradation of cartilage matrix.


Accordingly, disease states in which the IL-1 processing and release inhibitors of Formula 1 may be useful as therapeutic agents include, but are not limited to, infectious diseases where active infection exists at any body site, such as meningitis and salpingitis; complication of infections including septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome; acute or chronic inflammation due to antigen, antibody and/or complement deposition; inflammatory conditions including arthritis, cholangitis, colitis, encephalitis, endocarditis,

-3-

glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury and vasculitis. Immune-based diseases which may be responsive to IL-1 processing and release inhibitors of Formula 1 include but are not limited to conditions involving T-cells and/or macrophages such as acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease; auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis. IL-1 processing and release inhibitors of Formula 1 may also be useful in the treatment of bone and cartilage resorption as well as diseases resulting in excessing deposition of extracellular matrix. Such diseases include periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis and keloid formation. IL-1 processing and release inhibitors of Formula 1 may also be useful in treatment of certain tumors which produce IL-1 as an autocrine growth factor and in preventing the cachexia associated with certain tumors. IL-1 processing and release inhibitors of Formula 1 may also be useful in the treatment of neuronal diseases with an inflammatory component, including, but not limited to Alzheimers disease, depression and percussion injury. IL-1 processing and release inhibitors may also be useful in treating cardiovascular diseases in which recruitment of monocytes into the subendothelial space plays a role, such as the development of atherosclerotic plaques.

Summary of the Invention

The present invention relates to a compound of the formula




or a pharmaceutically acceptable salt thereof, wherein

R¹ is (C₁-C₆)alkyl optionally substituted by (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylamino, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroaryloxy, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₆)cycloalkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkyl(hydroxymethylene), piperazinyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy, (C₅-C₉)heteroaryl(C₁-C₆)alkoxy, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, (C₁-C₆)alkylsulfinyl, (C₆-C₁₀)arylsulfinyl, (C₁-C₆)alkylsulfonyl, (C₆-C₁₀)arylsulfonyl, amino, (C₁-C₆)alkylamino or ((C₁-C₆)alkyl)₂amino; or

-4-

R¹ and R² are each independently a group of the formula




wherein the broken lines represent optional double bonds;

n is 0, 1, 2 or 3;

- 10 A, B, D, E and G are each independently oxygen, sulfur, nitrogen or CR⁵R⁶ wherein R⁵ and R⁶ are each independently selected from hydrogen, (C₁-C₆)alkyl optionally substituted by one or two groups selected from (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, hydroxy, cyano, perfluoro(C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy wherein the aryl group
- 15 is optionally substituted by (C₁-C₆)alkoxy, (C₁-C₆)acyl, carboxy, hydroxy or halo; (C₅-C₉)heteroarylamino, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroaryloxy, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₆)cycloalkyl, hydroxy, piperazinyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy, (C₅-C₉)heteroaryl(C₁-C₆)alkoxy, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, (C₁-C₆)alkylsulfinyl, (C₆-C₁₀)arylsulfinyl, (C₁-C₆)alkylsulfonyl, (C₆-C₁₀)arylsulfonyl, amino, (C₁-C₆)alkylamino or
- 20 ((C₁-C₆)alkyl)₂amino; halo, cyano, amino, hydroxy, perfluoro(C₁-C₆)alkyl, perfluoro(C₁-C₆)alkoxy, (C₂-C₆)alkenyl, carboxy(C₂-C₆)alkenyl, (C₂-C₆)alkynyl, (C₁-C₆)alkylamino, ((C₁-C₆)alkyl)₂amino, (C₁-C₆)alkylsulfonylamido, (C₁-C₆)alkylsulfinyl, aminosulfonyl, (C₁-C₆)alkylaminosulfonyl, ((C₁-C₆)alkyl)₂aminosulfonyl, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, perfluoro(C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arylthio,
- 25 (C₆-C₁₀)aryl(C₁-C₆)alkoxy, (C₅-C₉)heteroarylamino, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroaryloxy, (C₃-C₆)cycloalkyl, (C₁-C₆)alkyl(hydroxymethylene), piperidyl, pyridinyl, thienyl, furanyl, (C₁-C₆)alkylpiperidyl, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, R⁷(C₁-C₆)alkyl wherein R⁷ is (C₁-C₆)acylpiperazino, (C₆-C₁₀)arylpiperazino, (C₅-C₉)heteroarylpiperazino, (C₁-C₆)alkylpiperazino, (C₆-C₁₀)aryl(C₁-C₆)alkylpiperazino, (C₅-C₉)heteroaryl(C₁-C₆)alkylpiperazino, morpholino, thiomorpholino, piperidino, pyrrolidino,
- 30 piperidyl, (C₁-C₆)alkylpiperidyl, (C₆-C₁₀)arylpiperidyl, (C₅-C₉)heteroarylpiperidyl, (C₁-C₆)alkylpiperidyl(C₁-C₆)alkyl, (C₆-C₁₀)arylpiperidyl(C₁-C₆)alkyl, (C₅-C₉)heteroarylpiperidyl(C₁-C₆)alkyl or (C₁-C₆)acylpiperidyl;

-5-

or a group of the formula



wherein s is 0 to 6;

10 t is 0 or 1;

X is oxygen or NR^8 wherein R^8 is hydrogen, $(\text{C}_1\text{-C}_6)\text{alkyl}$ or $(\text{C}_3\text{-C}_7)\text{cycloalkyl}(\text{C}_1\text{-C}_6)\text{alkyl}$;

Y is hydrogen, hydroxy, $(\text{C}_1\text{-C}_6)\text{alkyl}$, optionally substituted by halo, hydroxy or cyano; $(\text{C}_1\text{-C}_6)\text{alkoxy}$, cyano, $(\text{C}_2\text{-C}_6)\text{alkynyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}$ wherein the aryl group is optionally substituted by halo, hydroxy, carboxy, $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}$; perfluoro $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}(\text{C}_1\text{-C}_6)\text{alkyl}$ or NR^9R^{10} wherein R^9 and R^{10} are each independently selected from the group consisting of hydrogen, $(\text{C}_1\text{-C}_6)\text{alkyl}$ optionally substituted by $(\text{C}_1\text{-C}_6)\text{alkylpiperidyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl piperidyl}$, $(\text{C}_5\text{-C}_9)\text{heteroaryl piperidyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}$, $(\text{C}_5\text{-C}_9)\text{heteroaryl}$ or $(\text{C}_3\text{-C}_6)\text{cycloalkyl}$; piperidyl, $(\text{C}_1\text{-C}_6)\text{alkyl piperidyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl piperidyl}$, $(\text{C}_5\text{-C}_9)\text{heteroaryl piperidyl}$, $(\text{C}_1\text{-C}_6)\text{acyl piperidyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}$, $(\text{C}_5\text{-C}_9)\text{heteroaryl}$, $(\text{C}_3\text{-C}_6)\text{cycloalkyl}$, $\text{R}^{11}(\text{C}_2\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_5)\text{alkyl}(\text{CHR}^{11})(\text{C}_1\text{-C}_6)\text{alkyl}$ wherein R^{11} is hydroxy, $(\text{C}_1\text{-C}_6)\text{acyloxy}$, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, piperazino, $(\text{C}_1\text{-C}_6)\text{acylamino}$, $(\text{C}_1\text{-C}_6)\text{alkylthio}$, $(\text{C}_6\text{-C}_{10})\text{arylthio}$, $(\text{C}_1\text{-C}_6)\text{alkylsulfinyl}$, $(\text{C}_6\text{-C}_{10})\text{arylsulfinyl}$, $(\text{C}_1\text{-C}_6)\text{alkylsulfoxyl}$, $(\text{C}_6\text{-C}_{10})\text{arylsulfoxyl}$, amino, $(\text{C}_1\text{-C}_6)\text{alkylamino}$, $((\text{C}_1\text{-C}_6)\text{alkyl})_2\text{amino}$, $(\text{C}_1\text{-C}_6)\text{acylpiperazino}$, $(\text{C}_1\text{-C}_6)\text{alkyl piperazino}$, $(\text{C}_6\text{-C}_{10})\text{aryl}(\text{C}_1\text{-C}_6)\text{alkyl piperazino}$, $(\text{C}_5\text{-C}_9)\text{heteroaryl}(\text{C}_1\text{-C}_6)\text{alkyl piperazino}$, morpholino, thiomorpholino, piperidino or pyrrolidino; $\text{R}^{12}(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_5)\text{alkyl}(\text{CHR}^{12})(\text{C}_1\text{-C}_6)\text{alkyl}$ wherein R^{12} is piperidyl or $(\text{C}_1\text{-C}_6)\text{alkyl piperidyl}$; and $\text{CH}(\text{R}^{13})\text{COR}^{14}$ wherein R^{14} is as defined below and R^{13} is hydrogen, $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{aryl}(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_5\text{-C}_9)\text{heteroaryl}(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkylthio}(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{arylthio}(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkylsulfinyl}(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{arylsulfinyl}(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkylsulfonyl}(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_6\text{-C}_{10})\text{arylsulfonyl}(\text{C}_1\text{-C}_6)\text{alkyl}$, hydroxy $(\text{C}_1\text{-C}_6)\text{alkyl}$, amino $(\text{C}_1\text{-C}_6)\text{alkyl}$, $(\text{C}_1\text{-C}_6)\text{alkylamino}(\text{C}_1\text{-C}_6)\text{alkyl}$, $((\text{C}_1\text{-C}_6)\text{alkylamino})_2(\text{C}_1\text{-C}_6)\text{alkyl}$, $\text{R}^{15}\text{R}^{16}\text{NCO}(\text{C}_1\text{-C}_6)\text{alkyl}$ or $\text{R}^{15}\text{OCO}(\text{C}_1\text{-C}_6)\text{alkyl}$ wherein R^{15}


25

30

-6-

and R^{16} are each independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl, (C_6-C_{10}) aryl (C_1-C_6) alkyl and (C_5-C_9) heteroaryl (C_1-C_6) alkyl; and R^{14} is $R^{17}O$ or $R^{17}R^{18}N$ wherein R^{17} and R^{18} are each independently selected from the group consisting of hydrogen, (C_1-C_6) alkyl, (C_6-C_{10}) aryl (C_1-C_6) alkyl and (C_5-C_9) heteroaryl (C_1-C_6) alkyl;

5 or a group of the formula




wherein u is 0, 1 or 2;

R^{19} is hydrogen, (C_1-C_6) alkyl or perfluoro (C_1-C_6) alkyl;

R^{20} is hydrogen, (C_1-C_6) alkyl, (C_1-C_6) carboxyalkyl or (C_6-C_{10}) aryl (C_1-C_6) alkyl;

or a group of the formula



wherein a is 0, 1 or 2;

25 b is 0 or 1;

c is 1, 2 or 3;

d is 0 or 1;

e is 0, 1 or 2;


J and L are each independently oxygen or sulfur;

30 R^{21} is hydrogen, hydroxy, fluoro, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, halo (C_1-C_6) alkyl, amino, (C_1-C_6) acylamino or $NR^{26}R^{27}$ wherein R^{26} and R^{27} are each independently selected from hydrogen, (C_1-C_6) alkyl or (C_6-C_{10}) aryl; and

-7-

R^{22} is hydrogen, (C_1-C_6) alkyl optionally substituted by hydroxy, halo, (C_1-C_6) alkylthio, (C_1-C_6) alkylsulfinyl or (C_1-C_6) alkylsulfonyl;

or when n is 1 and B and D are both CR^5 , the two R^5 groups may be taken together with the carbons to which they are attached to form a group of the formula




10 wherein the broken lines represent optional double bonds;

m is 0 or 1; and

T, U, V and W are each independently oxygen, sulfur, CO, nitrogen or CR^5R^6 wherein R^5 and R^6 are as defined above;

15 or when A and B, or when n is 1 and B and D, or D and E, or E and G, are both CR^5 , the two R^5 groups may be taken together with the adjacent carbons to which they are attached to form a (C_5-C_6) cycloalkyl group optionally substituted by hydroxy or a benzo group;

or when n is 1 and D and E are both CR^5 , the two R^5 groups may be taken together with the adjacent carbons to which they are attached to form a group of the formula



30 wherein the broken line represents an optional double bond;

R^{23} is hydrogen, (C_1-C_6) alkyl, halo, amino or (C_1-C_6) alkoxy;

J is C or SO;

-8-

- K is oxygen, NR^{24} wherein R^{24} is hydroxy, $(\text{C}_1\text{-C}_6)\text{alkoxy}$ or $(\text{C}_6\text{-C}_{10})\text{aryl}(\text{C}_1\text{-C}_6)\text{alkoxy}$; or hydroxy;
or R^{25}SO_2 wherein R^{25} is defined as R^1 above or $(\text{C}_3\text{-C}_7)\text{cycloalkylamino}$; and
with the proviso that the groups of formulas II and VI cannot have two oxygens,
5 two sulfurs or an oxygen and sulfur defined in adjacent positions;
with the proviso that R^2 must be aromatic;
with the proviso that when either a or e is 0, the other must be 1;
with the proviso that when b and d are 1, the sum of a, c and e cannot be 6 or
7; and
10 with the proviso that when A, B, D, E, G, T, U, V and W represent an sp^2 carbon,
 R^6 does not exist.

The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or combinations thereof.

- 15 The term "alkoxy", as used herein, includes O-alkyl groups wherein "alkyl" is defined above.

- The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl, optionally substituted by 1 to 3 substituents selected from the group
20 consisting of fluoro, chloro, trifluoromethyl, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, $(\text{C}_6\text{-C}_{10})\text{aryloxy}$, trifluoromethoxy, difluoromethoxy and $(\text{C}_1\text{-C}_6)\text{alkyl}$.


- The term "heteroaryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic heterocyclic compound by removal of one hydrogen, such as pyridyl, furyl, pyrolyl, thienyl, isothiazolyl, imidazolyl, benzimidazolyl,
25 tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyl, purinyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzthiazolyl or benzoxazolyl, optionally substituted by 1 to 2 substituents selected from the group consisting of fluoro, chloro, trifluoromethyl, $(\text{C}_1\text{-C}_6)\text{alkoxy}$, $(\text{C}_6\text{-C}_{10})\text{aryloxy}$, trifluoromethoxy, difluoromethoxy and $(\text{C}_1\text{-C}_6)\text{alkyl}$.

- 30 The term "acyl", as used herein, unless otherwise indicated, includes a radical of the general formula RCO wherein R is alkyl, alkoxy, aryl, arylalkyl or arylalkyloxy and the terms "alkyl" or "aryl" are as defined above.

-9-

The term "acyloxy", as used herein, includes O-acyl groups wherein "acyl" is defined above.

Preferred compounds of formula I include those wherein R^1 is a group of the formula




wherein the broken lines represent double bonds;

n is 0 or 1;

15 A is CR^5 wherein R^5 is hydrogen or halo;

B and E are both independently CR^5 wherein R^5 is hydrogen cyano, halo, (C_1-C_6) alkyl optionally substituted by one or two hydroxy; (C_3-C_7) cycloalkylaminosulfonyl, (C_1-C_6) alkylaminosulfonyl, or a group of the formula



wherein s is 0;


t is 0; and

Y is hydrogen, (C_1-C_6) alkyl optionally substituted by halo; or (C_1-C_6) alkoxy (C_1-C_6) alkyl;

30 or a group of the formula

-10-

5



10 wherein a is 0 or 1;

b is 0 or 1;

c is 1 or 2;

d is 0 or 1;

e is 0 or 1;


15

J and L are each independently oxygen or sulfur;

 R^{21} is hydrogen, hydroxy or (C_1-C_6) alkyl optionally substituted by halo; and R^{22} is hydrogen or (C_1-C_6) alkyl optionally substituted by hydroxy, halo, (C_1-C_6) alkylthio, (C_1-C_6) alkylsulfinyl or (C_1-C_6) alkylsulfonyl;

or a group of the formula

20




25 wherein u is 0 or 1;

 R^{19} is (C_1-C_6) alkyl or trifluoromethyl; and R^{20} is hydrogen;D is CR^5 wherein R^5 is hydrogen, (C_1-C_6) alkyl or halo;G is CR^5 wherein R^5 is oxygen, sulfur or CR^5 wherein R^5 is hydrogen or halo;

30

or when n is 1 and B and D are both CR^5 , the two R^5 groups may be taken together with the carbons to which they are attached to form a group of the formula

-11-



wherein the broken lines represent double bonds;


m is 0;

T is oxygen, nitrogen or CR⁵ wherein R⁵ is hydrogen;

U is CO or CR⁵ wherein R⁵ is hydrogen; and

W is nitrogen or CR⁵ wherein R⁵ is hydrogen;

or when n is 1 and D and E are both CR⁵, the two R⁵ groups may be taken together with the adjacent carbons to which they are attached to form a group of the formula



wherein the broken line represents an optional double bond;


R²³ is hydrogen or (C₁-C₆)alkyl;

J is C or SO

K is oxygen, NR²⁴ wherein R²⁴ is hydroxy; or hydroxy.

Other preferred compounds of formula I include those wherein R² is a group of the formula

-12-



5


wherein the broken lines represent optional double bonds;

n is 1;

A is CR⁵ wherein R⁵ is halo or (C₁-C₆)alkyl;

10 B is CR⁵ wherein R⁵ is hydrogen or halo;

D is CR⁵ wherein R⁵ is hydrogen, halo, cyano or a group of the formula



15

wherein s is 0;

20 t is 0; and

Y is NH₂;

E is CR⁵ wherein R⁵ is hydrogen or halo; and

G is CR⁵ wherein R⁵ is halo or (C₁-C₆)alkyl;


or when A and B, or E and G, are both CR⁵, the two R⁵ groups may be taken
25 together with the adjacent carbons to which they are attached to form a (C₅-C₆)cycloalkyl group.

Other preferred compounds of formula I include those wherein R¹ is a group of the formula

30

-13-

5



wherein the broken lines represent double bonds;


10

n is 0 or 1;

A is CR^5 wherein R^5 is hydrogen or halo;

B and E are both independently CR^5 wherein R^5 is hydrogen cyano, halo, (C_1-C_6) alkyl optionally substituted by one or two hydroxy; (C_3-C_7) cycloalkylaminosulfonyl, (C_1-C_6) alkylaminosulfonyl, or a group of the formula

15



20

wherein s is 0;

t is 0; and


Y is hydrogen, (C_1-C_6) alkyl optionally substituted by halo; or (C_1-C_6) alkoxy(C_1-C_6)alkyl;

25

or a group of the formula

30

-14-



10 wherein a is 0 or 1;

b is 0 or 1;

c is 1 or 2;

d is 0 or 1;


e is 0 or 1;

15 J and L are each independently oxygen or sulfur;

R²¹ is hydrogen, hydroxy or (C₁-C₆)alkyl optionally substituted by halo; and

R²² is hydrogen or (C₁-C₆)alkyl optionally substituted by hydroxy, halo, (C₁-C₆)alkylthio, (C₁-C₆)alkylsulfinyl or (C₁-C₆)alkylsulfonyl;

or a group of the formula



25 wherein u is 0 or 1;

R¹⁹ is (C₁-C₆)alkyl or trifluoromethyl; and


R²⁰ is hydrogen;

D is CR⁵ wherein R⁵ is hydrogen, (C₁-C₆)alkyl or halo;

G is CR⁵ wherein R⁵ is oxygen, sulfur or CR⁵ wherein R⁵ is hydrogen or halo;

30 or when n is 1 and B and D are both CR⁵, the two R⁵ groups may be taken together with the carbons to which they are attached to form a group of the formula

-15-



5

wherein the broken lines represent double bonds;

m is 0;


T is oxygen, nitrogen or CR⁵ wherein R⁵ is hydrogen;

10 U is CO or CR⁵ wherein R⁵ is hydrogen; and

W is nitrogen or CR⁵ wherein R⁵ is hydrogen;

or when n is 1 and D and E are both CR⁵, the two R⁵ groups may be taken together with the adjacent carbons to which they are attached to form a group of the formula

15



20

wherein the broken line represents an optional double bond;


R²³ is hydrogen or (C₁-C₆)alkyl;

25 J is C or SO

K is oxygen, NR²⁴ wherein R²⁴ is hydroxy; or hydroxy; and

R² is a group of the formula

30



-16-


wherein the broken lines represent optional double bonds;

n is 1;

A is CR⁵ wherein R⁵ is halo or (C₁-C₆)alkyl;

B is CR⁵ wherein R⁵ is hydrogen or halo;

5 D is CR⁵ wherein R⁵ is hydrogen, halo, cyano or a group of the formula



wherein s is 0;

t is 0; and

15 Y is NH₂;

E is CR⁵ wherein R⁵ is hydrogen or halo; and

G is CR⁵ wherein R⁵ is halo or (C₁-C₆)alkyl;

or when A and B, or E and G, are both CR⁵, the two R⁵ groups may be taken together with the adjacent carbons to which they are attached to form a (C₅-C₆)cycloalkyl group.

20

Specific preferred compounds of formula I include the following:

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-1-methyl-ethyl)-benzenesulfonyl]-urea;

1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;

25

1-(1,2,3,5,6,7-Hexahydro-4-aza-s-indacen-8-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;

1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-thiophene-2-sulfonyl]-urea;

1-(4-[1,3]Dioxolan-2-yl-furan-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;

30

1-(2,6-Diisopropyl-phenyl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;

- 1-(2,6-Diisopropyl-phenyl)-3-[4-(1-hydroxy-1-methyl-ethyl)-thiophene-2-sulfonyl]-urea;
- 1-(4-Acetyl-thiophene-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;
- 1-(1H-Benzoimidazole-5-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;
- 5 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-thiophene-2-sulfonyl]-urea;
- 1-(8-Chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;
- 1-(4-Acetyl-furan-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;
- 10 1-(8-Fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;
- 1-(4-Fluoro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-1-methyl-ethyl)-benzenesulfonyl]-urea;
- 1-(6-Fluoro-1H-benzoimidazole-5-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;
- 15 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-(1H-indole-6-sulfonyl)-urea;
- 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-(5-fluoro-1H-indole-6-sulfonyl)-urea;
- 1-[1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-(1H-indole-6-sulfonyl)-urea;
- 1-(5-Fluoro-1H-indole-6-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-5-indacen-4-yl)-urea;
- 20 1-[4-Chloro-2,6-diisopropyl-phenyl]-3-[2-fluoro-5-(2-methyl-(1,3)dioxolan-2-yl)-benzenesulfonyl]-urea;
- 3-[3-[4-Chloro-2,6-diisopropyl-phenyl]-ureidosulfonyl]-N-methyl-benzenesulfonamide;
- 1-[2-Fluoro-5-(2-methyl-(1,3)dioxolan-2-yl)benzenesulfonyl]-3,1,2,3,5,6,7-hexahydro-indacen-4-yl)-urea; and
- 25 3-[3-(1,2,3,5,6,7-Hexahydro-S-indacen-4-yl)-ureidosulfonyl]-N-methyl-benzenesulfonamide.

The present invention also relates to a pharmaceutical composition for the treatment of meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases

30

-18-

including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation, tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzheimers disease, percussion injury, depression, atherosclerosis (including cardiomyopathy, myocarditis and heart failure) and osteoporosis in a mammal, including a human, comprising administering an amount of a compound of formula I or a pharmaceutically acceptable salt thereof, effective in such treatments or inhibition and a pharmaceutically acceptable carrier.

The present invention also relates to a method for treating a condition selected from the group consisting of meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation, tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzheimers disease, percussion injury, depression, atherosclerosis (including cardiomyopathy, myocarditis and heart failure) and osteoporosis in a mammal, including a human, comprising administering to said mammal an amount of a compound of formula I or a pharmaceutically acceptable salt thereof, effective in treating such a condition.


Detailed Description of the Invention

The following reaction Schemes illustrate the preparation of the present invention. Unless otherwise indicated n, A, B, D, E and G in the reaction Schemes and the discussion that follow are defined as above.

5


Preparation A

10




XII

15






20



XI


-20-

Preparation B



20

-21-

Preparation C




XVI




XV

-22-


Preparation D

XVIII

10




15



20

XVII

-23-

Scheme 1

In reaction 1 of Preparation A, the compound of formula **XII** is converted to the corresponding isocyanate compound of formula **XI** by reacting **XII** with triphosgene in the presence of a base, such as triethylamine, diisopropylethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene, and a aprotic solvent, such as tetrahydrofuran, benzene or methylene chloride. The mixture is stirred and heated to reflux for a time period between about 1 hour to about 3 hours, preferably about 2 hours.

In reaction 1 of Preparation B, the compound of formula **XIV** is converted to the corresponding sulfonamide compound of formula **XIII** by adding an alkyl lithium, such as n-butyl, sec-butyl or tert-butyl lithium, to a stirred solution of **XIV** in a polar solvent, such as tetrahydrofuran, at a temperature between about -70°C to about -85°C, preferably about -78°C. After approximately 15 minutes, liquified sulfur dioxide is added to the reaction mixture so formed, stirred at approximately -78°C for 5 minutes and then warmed to room temperature for a time period between about 1 hour to about 3 hours, preferably about 2 hours. The mixture is then (a) concentrated in vacuo, and treated with either a chlorinating reagent, such as N-chloro-succinimide in a polar solvent, such as methylene chloride, followed by treatment with gaseous or aqueous ammonia or (b) treated with hydroxylamine o-sulfonic acid in water in the presence of a buffer, such as sodium acetate.

In reaction 1 of Preparation C, the compound of formula **XVI** is converted to the corresponding sulfonamide compound of formula **XV** by adding a solution of sodium nitrate in water to a stirred solution of **XVI** in a mixture acetic acid and hydrochloric acid. Acetic acid saturated with sulfur dioxide gas is then added followed by cuprous chloride. The reaction mixture so formed is stirred at a temperature between about -10°C to about 10°C, preferably about 0°C, for a time period between about 1 hour to about 3 hours, preferably about 2 hours. The resulting sulfonyl chloride is then treated with gaseous or aqueous ammonia bubbled through a solution of the sulfonyl chloride in an aprotic solvent, such as methylene chloride or ether.

In reaction 1 of Preparation D, the compound of formula **XVIII** is converted to the corresponding sulfonamide compound of formula **XVII** by reacting **XVIII** with chlorosulfonic acid in a polar aprotic solvent, such as chloroform at a temperature between about -10°C to about 10°C, preferably about 0°C. The reaction mixture so formed is warmed to approximately 60°C. After a time period between about 1.5 hours to about 2.5 hours, preferably about 2 hours, the reaction mixture is once again cooled

-25-

to a temperature approximately 0°C and poured onto ice. The resulting sulfonyl chloride is then treated with gaseous or aqueous ammonia bubbled through a solution of the sulfonyl chloride in an aprotic solvent such as methylene chloride or ether.

In reaction 1 of Scheme 1, the isocyanate compound of formula X and the
5 sulfonamide compound of formula IX are converted to the corresponding sulfonyl urea compound of formula VII by reacting IX and X in the presence of a base, such as sodium hydride, sodium hydroxide, triethylamine or 1,8-diazabicyclo[5.4.0]undec-7-ene, and a polar solvent, such as tetrahydrofuran, acetone or dimethylformamide. The reaction mixture so formed is heated to reflux for a time period between about 10 hours
10 to about 14 hours, preferably about 12 hours.

Inhibition of ATP Induced Release of IL-1B

Mononuclear cells are purified from 100 ml of blood isolated using LSM (Organon Teknika). The heparinized blood (1.5 ml of 1000 units/ml heparin for injectin from Apotheconis added to each 50 ml syringe) is diluted with 20 ml of Medium (RMI
15 1640, 5% FBS, 1% pen/strep, 25 mM HEPES, pH 7.3). 30 ml of the diluted blood is layered over 15 ml of LSM (Organon Teknika) in a 50 ml conical polypropylene centrifuge tube. The tubes are centrifuged at 1200 rpm for 30 minutes in benchtop Sorvall centrifuge at room temperature. The mononuclear cells, located at the interface of the plasma and LSM, are removed, diluted with Medium to achieve a final volume of
20 50 ml, and collected by centrifugation as above. The supernatant is discarded and the cell pellet is washed 2 times with 50 ml of medium. A 10 µl sample of the suspended cells is taken before the second wash for counting; based on this count the washed cells are diluted with medium to a final concentration of 2.0 x 10⁶ cells/ml.

0.1 ml of the cell suspension is added to each well of 96 well plates. The
25 monocytes are allowed to adhere for 2 hours, then non-adherent cells are removed by aspiration and the attached cells are washed twice with 100 µl of Medium. 100 µl of Medium is added to each well, and the cells are incubated overnight at 37°C in a 5% carbon dioxide incubator.

The following day, 25 µl of 50 ng/ml LPS (in Medium) is added to each well and
30 the cells are activated for 2 hours at 37°C.

Test agents are diluted with dimethyl sulfoxide to a final concentration of 10 mM. From this stock solution compounds are first diluted 1:50 [5 µl of 10 mM stock + 245 µl Chase Medium (RPMI 1640, 25 mM Hepes, pH 6.9, 1% FBS, 1% pen/strep, 10 ng/ml

-26-

LPS and 5 mM sodium bicarbonate]. A second dilution is prepared by adding 10 μ l of the 200 μ M test agent to 90 μ l of Chase Medium yielding a final concentration of 20 μ M test agent; the dimethyl sulfoxide concentration at this point is 0.2%.

The LPS-activated monocytes are washed once with 100 μ l of Chase Medium then 100 μ l of Chase Medium (containing 0.2% dimethyl sulfoxide) is added to each well. 0.011 ml of the 20 μ M test agent solutions are added to the appropriate wells, and the monocytes are incubated for 30 minutes at 37°C. At this point 2 mM ATP is introduced by adding 12 μ l of a 20mM stock solution (previously adjusted to pH 7.2 with sodium hydroxide) and the cells are incubated for an additional 3 hours at 37°C.

The 96-well plates are centrifuged for 10 minutes at 2000 rpm in a Sorvall benchtop centrifuge to remove cells and cell debris. A 90 μ l aliquot of each supernatant is removed and transferred to a 96 well round bottom plate and this plate is centrifuged a second time to ensure that all cell debris is removed. 30 μ l of the resulting supernatant is added to a well of an IL-1 β ELISA plate that also contains 70 μ l of PBS, 1% FBS. The ELISA plate is incubated overnight at 4°C. The ELISA (R&D Systems) is run following the kit kirections.

Data Calculation and Analysis:

The amount of IL-1 β immunoreactivity in the chase medium samples is calculated as follows:

$$\% \text{ control} = (X-B) / (TOT-B) \times 100$$

where X = OD450 nm of test compound well

B = OD450 of Reagent Blank wells on the ELISA

TOT = O.D450 of cells that were treated with 0.2% dimethyl sulfoxide only.

The compounds of the present invention can be administered in a wide variety of different dosage forms, in general, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 5.0% to about 70% by weight.

For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicalcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably corn, potato or tapioca starch), alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelation and acacia.

Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

For parenteral administration (intramuscular, intraperitoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared. Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable intravenous injection purposes. The oily solutions are suitable for intraarticular, intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art.

The present invention is illustrated by the following examples, but it is not limited to the details thereof.

-28-

PREPARATION A3-Tert-butylsulfamoyl-benzenesulfonyl chloride

A solution of 1.46 grams (20 mmole) of t-butylamine and 2.02 grams (20 mmole) of triethylamine in tetrahydrofuran was added dropwise to a solution of 5.5 grams (20 mmole) of 1,3-benzenedisulfonyl chloride in tetrahydrofuran. The reaction was stirred at room temperature for 2 hours. The solvent was evaporated in vacuo. The residue was purified on silica gel eluting with methylene chloride to give 3.86 grams of the titled compound as an oil.

PREPARATION B

10 Benzene-1,3-disulfonic acid tert-butyl-amide methylamide

5 ml of a 33% solution of methylamine in ethanol was added to a solution of 1.8 grams (7 mmole) of 3-tert-butylsulfamoyl-benzenesulfonyl chloride in ethyl acetate. The mixture was stirred for 2 hours. The ethyl acetate layer was separated and concentrated in vacuo. The residue was purified on silica gel eluting 5% methanol in dichloromethane to give 1.32 grams of the titled compound as a white solid.

PREPARATION CBenzene-1,3-disulfonic acid tert-butyl-amide dimethylamide

Dimethylamine gas was allowed to bubble for 3 minutes into a solution of 1.8 grams (7 mmole) of 3-tert-butylsulfamoyl-benzenesulfonyl chloride in ethyl acetate. Water was added and the mixture was stirred at room temperature for 1 hour. The ethyl acetate layer was separated, dried over magnesium sulfate and concentrated in vacuo to a solid which was triturated with hexane/isopropyl ether to give 1.59 grams of the titled compound. m.p. 100-102°C.

PREPARATION D

25 Benzene-1,3-disulfonic acid amide tert-butyl amide

20 ml of concentrated ammonium hydroxide was added to a solution of 1 gram (3.2 mmole) 3-tert-butylsulfamoyl-benzenesulfonyl chloride in ethyl acetate. It was stirred vigorously for 8 hours. The ethyl acetate layer was separated dried over magnesium sulfate in vacuo to give 320 mg of the titled compound as a white solid. m.p. 151-154°C.

PREPARATION EBenzene-1,3-disulfonic acid tert-butyl-amide cyclopropylamide

A mixture of 5 ml of cyclopropylamine and 10 ml of water was added to a solution of 1 gram (3.9 mmole) of 3-tert-butylsulfamoyl-benzenesulfonyl chloride in ethyl acetate. The mixture was stirred at room temperature for 2 hours. The ethyl acetate layer was separated, dried over magnesium sulfate and concentrated in vacuo to an oil which crystallized from isopropyl ether to give 839 mg of the titled compound as a solid.

PREPARATION F

10 Benzene-1,3-disulfonic acid tert-butyl-amide cyclobutylamide

Using a procedure similar to that described in Preparation E, 4 ml of cyclobutylamine was added to 1 gram (3.9 mmole) of 3-tert-butylsulfamoyl-benzenesulfonyl chloride to give 813 mg of the titled compound.

PREPARATION G

15 Benzene-1,3-disulfonic acid amide methylamide

A solution of 1.3 grams (4.3 mmole) of benzene-1,3-disulfonic acid tert-butylamidemethylamide in 15 ml of trifluoroacetic acid containing 1 drop of anisole was stirred at room temperature for 12 hours. The trifluoroacetic acid was evaporated in vacuo and the residue triturated with methylene chloride to give 330 mg of the titled compound. mp: 124-126°C.

The titled compounds of Preparations H-J were prepared by a method analogous to that described in Preparation G using the starting material indicated.

PREPARATION HBenzene-1,3-disulfonic acid amide dimethylamide

25 Benzene-1,3-disulfonic acid tert-butyl-amide dimethylamide. mp: 166-167°C.

PREPARATION IBenzene-1,3-disulfonic acid amide cyclopropylamide

Benzene-1,3-disulfonic acid tert-butyl amide cyclopropylamide. mp: 120-121 °C.

PREPARATION J

30 Benzene-1,3-disulfonic acid amide cyclobutylamide

Benzene-1,3-disulfonic acid tert-butyl-amide cyclobutylamide. mp: 128-130°C.

-30-

PREPARATION K3-Methylsulfanyl-benzenesulfonamide

A solution of 1.6M n-butyllithium (12.5 ml, 20 mmol) in hexane was added to a solution of m-bromothioanisole (4.06 grams, 20 mmol). The solution so formed was stirred at -78°C for 3 hours. Sulfur dioxide was then bubbled into the reaction until it was acidic. The reaction was allowed to warm to room temperature overnight. A solution of N-chlorosuccinimide (2.4 grams, 78 mmol) in methylene chloride was added and after stirring for 1 hour at room temperature, the tetrahydrofuran was evaporated. The residue was slurried in methylene chloride and filtered. The filtrate was mixed with concentrated ammonium hydroxide and stirred at room temperature for 1 hour. The methylene chloride layer was dried and evaporated. The residue was triturated with methylene chloride to give 1.5 grams of the titled compound. mp: 126-127°C.

PREPARATION L3-Methanesulfinyl-benzenesulfonamide

A mixture of 3-methylsulfanyl-benzenesulfonamide (406 mg, 2 mmol) and N-chlorosuccinimide (268 mg, 2 mmol) in methanol was stirred at room temperature for 8 hours. The methanol was evaporated and the residue was slurried with methylene chloride and filtered. The filtrate was evaporated to give 250 mg of the titled compound as a white solid.

PREPARATION M3-Methanesulfonyl-benzenesulfonamide

To a solution of 3-methylsulfanylbenzenesulfonamide (500 mg, 2.5 mmol) in acetone was added an aqueous solution of OXONE® (3.2 grams, 5 mmol). The mixture was stirred at room temperature for 12 hours. The reaction was evaporated to dryness in vacuo. The residue was triturated with acetone and filtered. The filtrate was evaporated to give 460 mg of the titled compound.

PREPARATION N1-(3-Bromo-phenyl)-cyclobutanol

To a solution of 1,3-dibromo-benzene (2.36 grams, 10 mmol) in tetrahydrofuran at -78°C was added a 1.6M solution of n-butyllithium (6.3 ml, 10 mmol) in hexane and stirred for 4 hours. Cyclobutanone (700 mg, 10 mmol) was then added in one portion. After stirring for 2 hours at -78°C, the reaction was quenched with 2N hydrochloric acid. The reaction was warmed to room temperature, diluted with water and extracted with

-31-

ethyl acetate. The ethyl acetate layer was dried and evaporated to give 2.5 grams of crude product which was purified on silica gel eluting with 50% methylene chloride in hexane to give 1.5 grams of the titled compound.

PREPARATION O

5 3-(1-Hydroxy-cyclobutyl)-benzenesulfonamide

A 1.6M solution of n-butyllithium (8 ml, 12.8 mmol) in hexane was added to a solution of 1-(3-bromo-phenyl)-cyclobutanol (1.44 grams, 6.4 mmol) in tetrahydrofuran at -78°C. After 30 minutes, at the reaction was allowed to warm to 0°C. Sulfur dioxide was bubbled into the reaction mixture and stirred for an additional 30 minutes. The tetrahydrofuran was evaporated and an aqueous solution of sodium acetate (4.1 grams, 50 mmol) and of hydroxylamine-sulfonic acid (1.85 grams, 16 mmol) was added. After stirring at room temperature for 2 hours, the reaction was acidified with 2N hydrochloric acid then extracted with ethyl acetate. The ethyl acetate was dried over sodium sulfate and evaporated. The residue was purified on silica gel with dichloromethane/ether to give 70 mg of the titled compound.

PREPARATION P

1-(3-Bromophenyl)-cyclopentanol

Using a procedure similar to that of Preparation N, from 2.36 grams of 1,3-dibromobenzene, 6.3 ml of 1.6M n-butyllithium and 840 mg of cyclopentanone, there was obtained 1.56 grams of 1-(3-bromophenyl)-cyclopentanol as an oil.

PREPARATION Q

3-(1-Hydroxy-cyclopentyl)-6-benzenesulfonamide

Using a procedure similar to that of Preparation O, from 1.5 grams of 1-(3-bromo-phenyl)-cyclopentanol, 7.9 ml of 1.6M n-butyllithium, 1.85 grams of hydroxylamine-O-sulfonic acid and 4.1 grams of NaOAc, there was obtained 220 mg of 3-(1-hydroxy-cyclopentyl)-benzenesulfonamide as a white solid from dichloromethane. mp: 146-148°C.

PREPARATION R

1-(3-Bromophenyl)-cyclohexanol

Using a procedure similar to that of Preparation N, from 20 grams (85 mmole) of 1,3-dibromobenzene, 53 ml of 1.6M n-butyllithium in hexane and 8.3 grams of cyclohexanone, there was obtained 4.9 grams of 1-(3-bromophenyl)-cyclohexanol as a white solid.

-32-

PREPARATION S3-(1-hydroxy-cyclohexyl)-benzenesulfonamide

A 1.6M solution of n-butyllithium (12.35 ml, 19.8 mmol) in hexane was added to a solution of 1-(3-bromophenyl)-cyclohexanol (2.4 grams, 9.4 mmol) in tetrahydrofuran at -78°C. The reaction was stirred for 1 hour, then sulfur dioxide was bubbled into the solution until it was acidic to wet pH paper. The reaction was allowed to warm to room temperature over 12 hours. N-chlorosuccinimide (1.38 grams, 10.3 mmole), dissolved in dichloromethane was added and the reaction stirred for 2 hours. The tetrahydrofuran was evaporated and the residue slurried with methylene chloride and filtered. The filtrate was evaporated to 2.1 grams of 3-(1-hydroxy-cyclohexyl)-benzenesulfonyl chloride as a brown oil. This was dissolved in methylene chloride and added dropwise to 20 ml of liquid ammonia. The ammonia was allowed to evaporated and the residue purified on silica gel with dichloromethane/methanol to give 250 mg of the title compound as a white solid.

The titled compounds of Preparations T-V were prepared by a method analogous to that described in Preparation K using the starting material indicated.

PREPARATION T3-(2-Methyl-[1,3]dioxolan-2-yl)-benzenesulfonamide

2-(3-Bromophenyl)-2-methyl-[1,3]dioxolane. mp: 96-98°C.

PREPARATION U3-[1,3]Dioxolan-2-yl)-benzenesulfonamide

2-(3-Bromophenyl)-[1,3]-dioxolane. mp: 55-58°C.

PREPARATION V2-Fluoro-5-(2-methyl-[1,3]dioxolan-2-yl)-benzenesulfonamide

2-[3-Bromo-4-fluorophenyl]-2-methyl-[1,3]-dioxolane. mp: 149-150°C.

PREPARATION W[2-[4-bromo-2-nitro-phenyl]-vinyl]-dimethyl amine

A solution of 27 grams (.125 moles) of 4-bromo-1-methyl-2-nitrobenzene and 1 ml (.31 moles) of N,N-dimethylformamide dimethyl acetal in 120 ml of DMF was heated at 80° for 2 hours. After cooling, the reaction was poured onto water and extracted with ethylacetate. Then was dried over sodium sulfate and evaporated to give 36 grams of the titled compound as a purple solid.

-33-

PREPARATION XAcetic acid [2-(4-Bromo-2-nitro-phenyl)-ethylidene-hydrazide]

A solution of 36 grams of crude [2-[4-bromo-2-nitro-phenyl]-vinyl]-dimethylamine in 75 ml of dimethylformamide was cooled to 0°C. A solution of 26 grams of semicarbazide hydrochloride in 200 ml of water was added. 20 ml of concentrated hydrochloric acid was then added. The resulting solution was allowed to warm to room temperature. A tan precipitate was filtered, washed with water and dried.

PREPARATION Y6-Bromo-1H-indole

10 A solution of 375 grams of iron (II) sulfate heptahydrate in 700 ml of water was added to a suspension of 35 grams of crude acetic acid [2-(4-bromo-2-nitrophenyl)-ethylidene-hydrazide] 300 ml of concentrated ammonium hydroxide. The mechanically stirred mixture was heated to reflux for 4 hours, then cooled and filtered. The precipitate was triturated several times with hot ethyl acetate. The combined ethyl acetate layers were dried and evaporated to give 18 grams of the titled compound.

PREPARATION Z1H-Indole-6-sulfonic acid amide

To a suspension of 3.5 (.03 moles) of 35% KH in mineral oil in ether at 0°C was added dropwise a solution of 6.0 grams (.03 moles) of 6-bromo-1H-indole. After stirring for 1 hour, the light yellow solution was cooled to -78°C. 36.5 ml (.06 moles) of a 1.7M solution of t-btly lithium in pentane was added dropwise. After stirring for 1 hour at -78°C, SO₂ (g) was bubbled into the solution during 5 minutes. The reaction was allowed to warm to room temperature overnight. A solution of 4.1 grams (.03 moles) of N-chlorosuccinimide was added in one portion. After stirring for 1 hour, the reaction was filtered to remove succinimide and the filtrate evaporated to a yellow solid. This was dissolved in tetrahydrofuran and added to 20 ml of liquid ammonia. The reaction was allowed to warm to room temperature. The residue was dissolved in ethyl acetate, washed with water, dried and evaporated to give 1.4 grams of the titled compound.

PREPARATION AA5-Fluoro-2,3-dihydro-1H-indole

30 A solution of 6.8 grams (.05 moles) of 5-fluoro-1H-indole in 50 ml of ether was cooled to 0°C under nitrogen. 507 ml of a 0.15M solution of zinc borohydride in ether was added dropwise. The reaction was allowed to stir for 48 hours. The reaction was

-34-

quenched with dilute hydrochloric acid. The pH was adjusted to 8.0 with dilute sodium hydroxide. The ether layer was separated, dried and evaporated to give 7 grams of the titled compound.

PREPARATION BB

5 1-(5-Fluoro-2,3-dihydro-indol-yl)-ethanone

Acetyl chloride (3 ml) was added dropwise to a solution of 7 grams of crude 5-fluoro-2,3-dihydro-1H-indole and 3 ml of triethylamine in 100 ml of CH_2Cl_2 at 0°C. After two hours, the reaction was diluted with water. The methylene chloride layer was separated, dried and evaporated to afford 7.3 grams of crude product which was
10 purified on silica gel eluting with hexane/ethyl acetate to give 3.3 grams of the titled compound.

PREPARATION CC

1-Acetyl-5-fluoro-2,3-dihydro-1H-indole-6-sulfonic acid amide

Chlorosulfonic acid (35 ml) was cooled to 0°C under nitrogen. 3 grams (.016
15 moles) of 1-(5-fluoro-2,3-dihydro-indol-yl)-ethanone was added in portions. The reaction was heated a 50° for 3 hours, cooled and poured onto ice. The resulting white precipitate was filtered off and dissolved in methylene chloride. A solution of concentrated ammonium hydroxide was added and the mixture stirred at room temperature for 1 hour. The volatiles were evaporated in vacuo and dilute hydrochloric
20 acid was added. The precipitate was filtered and washed with water to give 3.6 grams of the titled compound.

PREPARATION DD

5-Fluoro-2,3-dihydro-1H-indole-6-sulfonic acid amide

A mixture of 3.6 grams of 1-Acetyl-5-fluoro-2,3-dihydro-1H-indole-6-sulfonic acid
25 amide and 30 ml of 2N sodium hydroxide was heated at 100°C for 3 hours. The reaction was cooled and the pH was adjusted to 7.0 with acetic acid. The resulting precipitate was filtered to give 3.0 grams of the titled compound.

PREPARATION EE

5-Fluoro-1H-indole-6-sulfonic acid amide

30 A mixture of 3 grams of manganese dioxide and 3 grams of 5-fluoro-2,3-dihydro-1H-indole-6-sulfonic acid amide in 30 ml of dioxane was heated at 50° overnight. The reaction was filtered and the filtrate was evaporated to afford crude product which was

-35-

purified on silica gel eluting with methylene chloride/ethyl acetate to give 1.1 grams of the titled compound. mp: 181-182°C.

PREPARATION FF

2-(3-Bromophenyl)-propan-2-ol

5 To a stirred solution of methylmagnesium bromide (60 mL of a 3.0 M solution in diethyl ether) at 0°C was added dropwise a solution of 3-bromoacetophenone (29.8 grams) in 75 mL of diethyl ether. Once the addition was complete, the mixture was stirred for 0.5 hours and poured into water. The aqueous phase was acidified with 1M hydrochloric acid and extracted with three portions of diethyl ether. The combined
10 ether layers were washed with saturated sodium bicarbonate, concentrated to afford 30.4 grams of the title compound. ¹H NMR δ 7.72 (br s, 1), 7.49 (d, 1, J = 7.8), 7.37 (d, 1, J = 7.9), 7.25 (dd, 1, J = 7.8, 7.9), 4.19 (s, 1), 1.50 (br s, 6).

PREPARATION GG

2-(3-Aminosulfonylphenyl)-propan-2-ol

15 To a stirred solution of 2-(3-bromophenyl)-propan-2-ol (30 grams) in tetrahydrofuran (1.5 L) at -78°C was added methyllithium (110 mL of a 1.4 M solution in diethyl ether). The solution was stirred at -78°C for 15 minutes, then butyllithium (61 mL of a 2.5 M solution in hexane) was added. The solution was stirred for 15 minutes at -78°C at which point a slurry formed. To this slurry was added liquified sulfur dioxide
20 (approximately 5 equivalents) in one portion. The slurry was stirred at -78°C for 5 minutes, then warmed to room temperature and stirred for an additional two hours. The mixture was concentrated in vacuo to afford a yellow solid which was taken up in water (418 mL). Sodium acetate (190 grams) and hydroxylamine O-sulfonic acid (47.3 grams) were added to the aqueous solution, and the solution was stirred overnight.
25 The mixture was extracted with ethyl acetate and the organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated in vacuo. Purification by flash chromatography (2:1 ethyl acetate/hexane) gave 27 grams of the title compound, m.p. 107.2-108.2°C.

PREPARATION HH

4-Chloro-2,6-diisopropylaniline

30 To a stirred solution of 2,6-diisopropylaniline (47 grams) in N,N-dimethylformamide (886 mL) was added N-chlorosuccinimide (37.3 grams) and the mixture was stirred overnight. The resulting dark red solution was poured into water

-36-

(12 L) and extracted with diethyl ether. The combined ether extracts were washed with water and brine, dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting dark red oil was purified by filtration through silica gel, eluting with 6:1 hexane/methylene chloride to afford 32 grams of the title compound. ¹H NMR δ 7.02 (s, 2), 3.71 (br s, 2), 2.91 (qq, 2, J = 6.9 Hz), 1.27 (d, 6, J = 6.9 Hz), 1.27 (d, 6, J = 6.9 Hz).

PREPARATION II

4-Chloro-2,6-diisopropylphenylisocyanate

To a stirred solution of 4-chloro-2,6-diisopropylaniline (32 grams) and triethylamine (7.8 mL) in tetrahydrofuran (505 mL) was added triphosgene (14.9 grams). The mixture was refluxed for two hours with stirring. The tetrahydrofuran was then revolved in vacuo and the resulting oil was taken up in pentane and filtered through silica gel to afford 33.3 grams of the product. ¹H NMR δ 7.18 (s, 2), 3.22 (qq, 2, J = 7.1 Hz), 1.25 (d, 6, J = 7.1 Hz), 1.25 (d, 6, J = 7.1 Hz).

PREPARATION JJ

2-[3-[[[(4-Chloro-2,6-diisopropylphenylamino)amino]carbonyl]amino[sulfonyl]phenyl]-propan-2-ol

To a stirred solution of 2-(3-aminosulfonylphenyl)-propan-2-ol (26.5 grams) in tetrahydrofuran was added sodium hydride (5.2 grams of a 60% dispersion in mineral oil) in several portions. Once hydrogen evolution had subsided, 4-chloro-2,6-diisopropylphenylisocyanate (30.8 grams) was added in one portion, and the resulting mixture was heated to reflux for twelve hours. The mixture was then cooled to room temperature and concentrated in vacuo. The resulting foam was dissolved in water, made basic with 1N sodium hydroxide and extracted with two portions of 1:1 ether/hexane. The aqueous layer was acidified with 1N hydrochloric acid, and the resulting white solid was filtered, washed with water and dried. This afforded 50 grams of a white solid which was recrystallized from wet ethyl acetate/hexane afforded the title compound, melting point 160.5-162.0°C.

PREPARATION KK

5-Nitroisophthaloyl chloride

To a stirred solution of 5-nitroisophthalic acid (10 grams) in methylene chloride (943 mL) was added oxalyl chloride (12.3 mL) and N,N-dimethylformamide (1 drop). The

-37-

reaction mixture was stirred at room temperature overnight. Removal of the solvent in vacuo afforded 10.63 grams of the title compound. ^1H NMR δ 9.17 (s, 2), 9.07 (s, 1).

PREPARATION LL

3,5-Diacetylnitrobenzene

- 5 Magnesium turnings (2.27 grams) were stirred with ethanol (12 mL) and carbon tetrachloride (1 drop). Once hydrogen evolution was complete, diethyl malonate (15.18 grams) in diethyl ether (30 mL) was added and the mixture was refluxed until all of the magnesium was consumed. 5-Nitroisophthaloyl chloride (10 grams) in tetrahydrofuran (29 mL) was added to the mixture and reflux was continued for an additional 16 hours.
- 10 The mixture was cooled in an ice bath and acidified with 10% sulfuric acid. The aqueous phase was extracted with ethyl acetate and the organic phase was concentrated in vacuo. The oily residue was taken up in acetic acid (72 mL) and water (14 mL) and sulfuric acid (4 mL) was added. The mixture was vigorously refluxed for 12 hours, then cooled in an ice bath. The mixture was neutralized with 3M sodium
- 15 hydroxide and extracted with ethyl acetate. The organic phase was dried over sodium sulfate and concentrated in vacuo to afford 7.54 grams of the title compound. ^1H NMR δ 8.90 (s, 2), 8.86 (s, 1), 2.78 (s, 6).

PREPARATION MM

3,5-Diacetylaniline

- 20 To a stirred solution of tin (II) chloride dihydrate (32.87 grams) in concentrated hydrochloric acid (93 mL) at 50°C was added 3,5-diacetylnitrobenzene (7.54 grams). The heat was removed immediately and an exotherm occurred. The mixture was stirred for 5 minutes, cooled with an ice bath, and neutralized with saturated potassium carbonate solution. The aqueous phase was extracted with several portions of ethyl
- 25 acetate, dried over anhydrous sodium sulfate and concentrated in vacuo to afford 3.01 grams of the title compound. ^1H NMR δ 7.77 (s, 1), 7.48 (s, 2), 5.16 (br s, 2), 2.55 (s, 6).

PREPARATION NN

3,5-Diacetylbenzenesulfonamide

- 30 To a stirred solution of 3,5-diacetylaniline (3.00 grams) in a mixture of acetic acid (17 mL) and hydrochloric acid (5.7 mL) was added a solution of sodium nitrate (1.27 grams) in 2.1 mL of water. The solution was stirred for 20 minutes. 14 mL of acetic acid was saturated with sulfur dioxide gas, and this mixture was added to the reaction,

-38-

followed by cuprous chloride (0.63 grams). Significant foaming occurred. The reaction mixture was stirred for one hour, diluted with water, and extracted with three portions of ethyl acetate. The combined ethyl acetate extracts were washed with water, and concentrated. The resulting oil was taken up in diethyl ether, and ammonia gas was bubbled through the solution. The resulting slurry was filtered, and the solid was taken up in acetone and filtered to remove ammonium chloride. Removal of the acetone in vacuo afforded 1.48 grams of the title compound, m.p. 179.2-180.7°C.

PREPARATION OO

1-[3-[[[(4-Chloro-2,6-diisopropylphenylamino)carbonyl]amino]sulfonyl]-5-acetylphenyl]-ethan-1-one

The title compound was prepared as described in method A from 3,5-diacetylbenzenesulfonamide (0.35 grams), 4-chloro-2,6-diisopropylphenylisocyanate (0.37 grams), sodium hydride (0.06 grams of a 60% dispersion in mineral oil), in tetrahydrofuran (4 mL). This afforded 0.28 grams of the title compound, m.p. 201.9-203.4°C.

PREPARATION PP

3-Chloro-1-indan-5-yl-propan-1-one

To a stirred solution of indane (300 grams) and 3-chloropropionoyl chloride (323 grams) in methylene chloride (2L) at 0°C was added aluminum chloride (376 grams) over a period of 3 hours. Once the addition was complete, the cooling bath was removed and the mixture was warmed to room temperature and stirred until hydrogen chloride evolution ceased. The reaction was quenched by pouring onto a mixture of 3.5 kg of ice and 700 mL of concentrated hydrochloric acid. The layers were separated, and the aqueous phase was extracted with methylene chloride. The combined methylene chloride layers were washed with water, saturated sodium bicarbonate solution and brine. The organic phase was dried with anhydrous sodium sulfate and concentrated in vacuo. The residue was recrystallized from hexane to afford 282 grams of a yellow solid, m.p. 63.5-65.1°C.

PREPARATION QQ

3,5,6,7-Tetrahydro-2H-s-indacen-1-one

Concentrated sulfuric acid (550 mL) was added dropwise, with stirring over a time period of 2 hours to 137 grams of 3-chloro-1-indan-5-yl-propan-1-one. The resulting thick black solution was heated to 90°C until hydrogen chloride evolution

-39-

ceased (usually 1-4 hours). The mixture was then cooled to room temperature and poured onto 5 kg of ice. The resulting slurry was stirred overnight and filtered. The solid was washed with water until the water ran clear through the filter. The tan solid was then dried in vacuo and recrystallized from hexane to afford 90 grams of the title compound, m.p. 72.4-74.8°C.

PREPARATION RR

1,2,3,5,6,7-Hexahydro-s-indacene

A mixture of 3,5,6,7-tetrahydro-2H-s-indacen-1-one (90 grams), ethanol (1L), 10% palladium on carbon (1-2 grams) and concentrated hydrochloric acid (50 mL) was hydrogenated on a Parr shaker at room temperature until hydrogen uptake ceased. The mixture was filtered through a Celite pad. The pad was washed with 1L diethyl ether. The filtrate was diluted with water and the organic phase was separated. The aqueous phase was extracted with 1L of ether, and the combined ether extracts were washed with water, saturated sodium bicarbonate solution and brine. The ether extracts were dried over anhydrous sodium sulfate and concentrated in vacuo. The resulting pale yellow solid was recrystallized from methanol to afford 61 grams of the title compound as colorless crystals, m.p. 56.6-58.5°C.

PREPARATION SS

1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-ethanone

To a stirred solution of 1,2,3,5,6,7-hexahydro-s-indacene (30 grams) and acetyl chloride (14.2 mL) in 120 mL of benzene at 0°C was added 30 grams of aluminum chloride over a period of 1 hour. The cooling bath was removed and the solution was warmed to room temperature and stirred for 4 hours. The deep red mixture was then poured onto a mixture of 270 grams of ice and 50 mL of concentrated hydrochloric acid. The layers were separated and the aqueous phase was extracted with diethyl ether. The combined organic phases were washed with saturated sodium bicarbonate solution and brine, dried over anhydrous sodium sulfate and concentrated in vacuo to afford an orange solid which was recrystallized from hexane to give 34 grams of the title compound, m.p. 69.1-76.1°C.

PREPARATION TT1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-ethanone oxide

A mixture of 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-ethanone (33 grams), ethanol (250 mL) hydroxylamine hydrochloride (58.5 grams) and pyridine (80 mL) was heated to reflux for a period of 12 hours. The mixture was then cooled to room temperature and concentrated in vacuo. The residue was then treated with 500 mL of water and extracted with chloroform-methanol. The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuo to afford 32 grams of the title compound as a mixture of E and Z isomers, 178.6-182.3°C.

PREPARATION UUN-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-acetamide

A mixture of 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-ethanone oxime (85 grams) in 270 mL of trifluoroacetic acid was added dropwise to a stirred refluxing solution of 90 mL of trifluoroacetic acid over a period of ½ hour. The resulting purple solution was then refluxed for 1 hour. The solution was cooled to room temperature and the trifluoroacetic acid was removed in vacuo. The dark solid was triturated with ethyl acetate/hexanes to afford 83 grams of a grey solid which was used without further purification, m.p. 257.4-259.1°C.

PREPARATION VV1,2,3,5,6,7-Hexahydro-s-indacen-4-ylamine

A slurry of N-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-acetamide (110 grams) in YY mL of 25% sulfuric acid was treated with enough ethanol to make a solution (ca YY mL). The resulting solution was heated to reflux for a period of 2 days. The resulting black solution was treated with charcoal at reflux, filtered hot and cooled to 0°C. The solution was then cautiously neutralized with 20% sodium hydroxide solution. The resulting slurry was then filtered and washed with water until the filtrate ran neutral. The tan solid was then isolated and dried in vacuo to give 80 grams of the title compound, m.p. 94.5-96.6°C, which was used without further purification. If necessary, the title compound can be recrystallized from methanol to afford a white solid.

PREPARATION WW1,2,3,5,6,7-Hexahydro-s-indacene

To a stirred solution of 1,2,3,5,6,7-hexahydro-s-indacen-4-ylamine (77 grams) in tetrahydrofuran (1.5 L) and triethylamine (68.3 mL) was added triphosgene (43.9 grams)

-41-

in one portion. The mixture was heated to reflux for ½ hour, then cooled to room temperature. The tetrahydrofuran was removed under reduced pressure, and the residue was taken up in pentane and filtered through a plug of silica gel. Removal of the pentane in vacuo afforded 80 grams of a white solid, m.p. 35.0-36.2°C.

5

PREPARATION XX3-(1-Hydroxy-1-methyl)ethylfuran

To a stirred solution of 24.97 mL of methyl magnesium bromide (3M solution in diethyl ether) at 0°C was added 4.82 mL of ethyl 3-furoate in diethyl ether. The mixture was heated gently using a warm water bath for 30 minutes. Upon completion, the mixture was poured into ice water, carefully acidified using a buffered solution, and extracted with diethyl ether. The ether extracts were combined, washed with brine, dried over sodium sulfate, and concentrated in vacuo. The tertiary alcohol furan was purified using flash column chromatography with 6:1 hexane/ethyl acetate. Recovery: 2.89 grams (64%). ¹H NMR (400 MHz, Acetone-d₆) δ 1.45 (s, 3H), 1.46 (s, 3H), 3.89 (br s, 1H), 6.45 (br s, 1H), 7.41 (br s, 1H), 7.42 (br s, 1H).

15

PREPARATION YY2-Aminosulfonyl-3-(1-hydroxy-1-methyl)ethylfuran

To a stirred mixture of 2.89 grams of tertiary alcohol furan in THF at -78°C was added 17.19 mL of methyl lithium (1.4M solution in diethyl ether) followed 5 minutes later by 18.51 mL of sec-butyl lithium (1.3M solution in cyclohexanes). The mixture continued to stir at -78°C for 40 minutes and 5.02 mL of liquid SO₂ was added. The temperature was maintained at -78°C for 5 minutes and was then warmed to room temperature with continued stirring for 2 hours. The THF was then removed in vacuo and the lithium sulfinat was dissolved in 76.4 mL of water followed by addition of 7.78 grams of hydroxylamine o-sulfonic acid and 31 grams of sodium acetate. This mixture stirred at room temperature overnight and was extracted with ethyl acetate. The ethyl acetate extracts were combined, washed with brine, dried over sodium sulfate, and concentrated in vacuo. The sulfonamide was purified using flash column chromatography with 2:1 hexane/ethyl acetate. Recovery: 1.91 grams (41%) m.p. 110.1-111.6°C.

20
25
30

-42-

PREPARATION ZZ

3-(1-Hydroxy-1-methyl)ethylthiophene

To a stirred solution of 3.17 mL of methyl magnesium bromide (3M solution in diethyl ether) at 0°C was added 1 gram of 3-acetylthiophene in diethyl ether. The mixture was then allowed to stir for 30 minutes while warming to room temperature. Upon completion, the mixture was poured into ice water, acidified, and extracted with diethyl ether. The ether extracts were combined, washed with brine, dried over sodium sulfate, and concentrated in vacuo. Recovery: 800 mg (71%) ¹H NMR (400 MHz, Acetone-d₆) δ 1.50 (s, 6H), 4.00 (br s, 1H), 7.15 (dd, 1H, J=1.4, 5), 7.23 (m, 1H), 7.33 (dd, 1H, J=3.1, 5).

PREPARATION AAA

2-Aminosulfonyl-3-(1-hydroxy-1-methyl)ethylthiophene

To a stirred mixture of 800 mg of tertiary alcohol thiophene in THF at 78°C was added 4.22 mL of methyllithium (1.4M solution in diethyl ether) followed 5 minutes later by 4.55 mL of sec-butyl lithium (1.3M solution in cyclohexanes). The mixture continued to stir at -78°C for 40 minutes and 1.23 mL of liquid SO₂ was added. The temperature was maintained at -78°C for 5 minutes and was then warmed to room temperature with continued stirring for 2 hours. The THF was then removed in vacuo and the lithium sulfinatate was dissolved in 19 mL of water followed by addition of 1.9 grams of hydroxylamine o-sulfonic acid and 7.66 grams of sodium acetate. This mixture stirred at room temperature overnight and was extracted with ethyl acetate. The ethyl acetate extracts were combined, washed with brine, dried over sodium sulfate, and concentrated in vacuo. The sulfonamide was purified using flash column chromatography with 2:1 hexane/ethyl acetate. Recovery: 600 mg (48%) m.p. 114.3-115.1°C.

EXAMPLE 1

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-1-methylethyl)-benzenesulfonyl]-urea

To a stirred solution of 2-(3-aminosulfonylphenyl)-propan-2-ol (26.5 grams) in tetrahydrofuran was added sodium hydride (5.2 grams of a 60% dispersion in mineral oil) in several portions. Once hydrogen evolution had subsided, 4-chloro-2,6-diisopropylphenylisocyanate (30.8 grams) was added in one portion, and the resulting mixture was heated to reflux for twelve hours. The mixture was then cooled to room temperature and concentrated in vacuo. The resulting foam was dissolved in water,

made basic with 1N sodium hydroxide and extracted with two portions of a 1:1 ratio of ether/hexane. The aqueous layer was acidified with 1N hydrochloric acid, and the resulting white solid was filtered, washed with water and dried. This afforded 50 grams of a white solid which was recrystallized from wet ethyl acetate/hexane afforded the title 5 compound, melting point 160.5-162.0°C.

The titled compounds of Example 2-130 were prepared by a method analogous to that described in Example 1 using the reagents indicated.

EXAMPLE 2

10 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxycyclopentyl)-benzenesulfonyl]-urea
3-1-Hydroxycyclopentyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 155°C.

EXAMPLE 3

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-methylsulfamoyl-benzenesulfonyl]-urea
3-Methylsulfamoyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
15 isocyanate. mp: 125-128°C.

EXAMPLE 4

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-dimethylsulfamoyl-benzenesulfonyl]-urea
3-Dimethylsulfamoyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 101-106°C.

20 EXAMPLE 5

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-cyclopropylsulfamoyl-benzenesulfonyl]-urea
3-Cyclopropylsulfamoyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 170-174°C.

EXAMPLE 6

25 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-cyclobutylsulfamoyl-benzenesulfonyl]-urea
3-Cyclobutylsulfamoyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 140-143°C.

EXAMPLE 7

30 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-methylsulfanyl-benzenesulfonyl]-urea
 3-Methylsulfanyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
 isocyanate. mp: 125-126°C.

-44-

EXAMPLE 81-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-methanesulfinyl-benzenesulfonyl]-urea

3-Methylsulfinyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate.
mp: 226-227°C.

5

EXAMPLE 91-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-methanesulfonyl-benzenesulfonyl]-urea

3-Methylsulfonyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: °C.

EXAMPLE 1010 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxycyclobutyl)-benzenesulfonyl]-urea

3-1-Hydroxycyclobutyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 155-157°C.

EXAMPLE 1115 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxycyclopentyl)-benzenesulfonyl]-urea

3-1-Hydroxycyclopentyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 155°C.

EXAMPLE 1220 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxycyclohexyl)-benzenesulfonyl]-urea

3-1-Hydroxycyclohexyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 172-176°C.

EXAMPLE 131-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(2-methyl-[1,3]dioxolan-2-yl)-benzenesulfonyl]-
urea25

3-(2-Methyl-[1,3]dioxolan-2-yl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-
phenyl isocyanate. mp: 155-157°C.

EXAMPLE 141-(4-Chloro-2,6-diisopropyl-phenyl)-3-(3-[1,3]dioxolan-2-yl-benzenesulfonyl)-urea

3-([1,3]Dioxolan-2-yl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 145-147°C.

30

-45-

EXAMPLE 15

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-(2-fluoro-5-(2-methyl-[1,3]-dioxolan-2-yl)-benzenesulfonyl)-urea

3-(2-Fluoro-5-(2-methyl-[1,3]dioxolan-2-yl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 168-170°C.

EXAMPLE 16

1-[2-Fluoro-5-(2-methyl-(1,3)-dioxolan-2-yl)benzenesulfonyl]-3-(1,2,3,5,6,7-hexahydro-5-indacen-4-yl)urea

EXAMPLE 17

10 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[1H-indole-6-sulfonyl]-urea

3-(1H-indole-6-sulfonamide)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 220-221°C.

EXAMPLE 18

1-(1,2,3,5,6,7-Hexahydro-5-indacen-4-yl)-3-[1H-indole-6-sulfonyl]-urea

15

EXAMPLE 19

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-(5-fluoro-1H-indole-6-sulfonyl)-urea

3-(5-Fluoro-1H-indole-6-sulfonamide)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 226-227°C.

EXAMPLE 20

20 1-[5-Fluoro-1H-indole-6-sulfonyl]-3-(1,2,3,5,6,7-hexahydro-5-indacen-4-yl)urea

EXAMPLE 21

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-ethyl)-5-trifluoromethyl-benzenesulfonyl]-urea

25 3-(1-Hydroxy-ethyl)-5-trifluoromethyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 168.9-170.0°C.

EXAMPLE 22

1-(3-Acetyl-5-trifluoromethyl-benzenesulfonyl)-3-(4-chloro-2,6-diisopropyl-phenyl)-urea

3-Acetyl-5-trifluoromethyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 157.4-158.9°C.

30

EXAMPLE 23

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-ethyl)-4-methyl-benzenesulfonyl]-urea
3-(1-Hydroxy-ethyl)-4-methyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 155.2-158.2°C.

5

EXAMPLE 24

1-(3-Acetyl-4-methyl-benzenesulfonyl)-3-(4-chloro-2,6-diisopropyl-phenyl)-urea
3-Acetyl-4-methyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 152.5-154.6°C.

EXAMPLE 25

10 1-[3,5-Bis-(1-hydroxy-ethyl)-benzenesulfonyl]-3-(4-chloro-2,6-diisopropyl-phenyl)-urea
3,5-Bis-(1-hydroxy-ethyl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 175.3-176.8°C.

EXAMPLE 26

15 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-ethyl)-5-iodo-benzenesulfonyl]-urea
3-(1-Hydroxy-ethyl)-5-iodo-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 184.4-186.6°C.

EXAMPLE 27

1-(3-Acetyl-5-iodo-benzenesulfonyl)-3-(4-chloro-2,6-diisopropyl-phenyl)-urea
3-Acetyl-5-iodo-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate.
20 mp: 187.6-188.9°C.

EXAMPLE 28

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[4-fluoro-3-(1-hydroxy-ethyl)-benzenesulfonyl]-urea
4-Fluoro-3-(1-hydroxy-ethyl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 149.7-151.8°C.

25

EXAMPLE 29

1-(3-Acetyl-4-fluoro-benzenesulfonyl)-3-(4-chloro-2,6-diisopropyl-phenyl)-urea
3-Acetyl-4-fluoro-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 171.8-173.4°C.

EXAMPLE 30

30 1-(4-Acetyl-thiophene-2-sulfonyl)-3-(4-chloro-2,6-diisopropyl-phenyl)-urea
4-Acetyl-thiophene-2-sulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate.
mp: 169.7-171.8°C.

-47-

EXAMPLE 31

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[4-(1-hydroxy-ethyl)-thiophene-2-sulfonyl]-urea
4-(1-Hydroxy-ethyl)-thiophene-2-sulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 164.5-166.6°C.

5

EXAMPLE 32

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(2-hydroxyimino-propyl)-benzenesulfonyl]-urea
3-(2-Hydroxyimino-propyl)-benzenesulfonyl; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 153.8-156.7°C.

EXAMPLE 33

10 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(2-hydroxy-propyl)-benzenesulfonyl]-urea
3-(2-Hydroxy-propyl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 148.7-149.9°C.

EXAMPLE 34

15 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(2-oxo-propyl)-benzenesulfonyl]-urea
3-(2-Oxo-propyl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 154.8-156.6°C.

EXAMPLE 35

1-(2,6-Diisopropyl-phenyl)-3-(3-propionyl-benzenesulfonyl)-urea
3-Propionyl-benzenesulfonamide; 2,6-Diisopropyl-phenylisocyanate. mp: 151.7-
20 152.8°C.

EXAMPLE 36

1-(3-Acetyl-4-methoxy-benzenesulfonyl)-3-(4-chloro-2,6-diisopropyl-phenyl)-urea
3-Acetyl-4-methoxy-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 214.2-215.1°C.

25

EXAMPLE 37

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-ethyl)-4-methoxy-benzenesulfonyl]-
urea
3-(1-Hydroxy-ethyl)-4-methoxy-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-
phenyl isocyanate. mp: 164.9-166.1°C.

30

EXAMPLE 38

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-propyl)-benzenesulfonyl]-urea
3-(1-Hydroxy-propyl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 218.4-220.3°C.

-48-

EXAMPLE 391-(4-Chloro-2,6-diisopropyl-phenyl)-3-(3-propionyl-benzenesulfonyl)-urea

3-Propionyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate.
mp: 149.1-152.2°C.

5

EXAMPLE 401-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-ethyl)-benzenesulfonyl]-urea

3-(1-Hydroxy-ethyl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 151.8-154.3°C.

EXAMPLE 4110 1-(5-Acetyl-2-methoxy-benzenesulfonyl)-3-(4-bromo-2,6-diisopropyl-phenyl)-urea

5-Acetyl-2-methoxy-benzenesulfonamide; 4-Bromo-2,6-diisopropyl-phenyl
isocyanate. mp: 185.1-186.5°C.

EXAMPLE 421-(5-Acetyl-2-methoxy-benzenesulfonyl)-3-(2,6-diisopropyl-phenyl)-urea15

5-Acetyl-2-methoxy-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp:
199.7-201.3°C.

EXAMPLE 431-(3-Acetyl-benzenesulfonyl)-3-(4-chloro-2,6-diisopropyl-phenyl)-urea20

3-Acetyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp:
163.1-165.6°C.

EXAMPLE 441-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxyimino-ethyl)-benzenesulfonyl]-urea

3-(1-Hydroxyimino-ethyl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 158.4-160.0°C.

25

EXAMPLE 451-(4-Bromo-2,6-diisopropyl-phenyl)-3-(6-methyl-1,1-dioxo-1-thiochroman-7-sulfonyl)-urea

6-Methyl-1,1-dioxo-1-thiochroman-7-sulfonamide; 4-Bromo-2,6-diisopropyl-phenyl
isocyanate. mp: 250.4-251.9°C.

EXAMPLE 4630 1-(2,6-Diisopropyl-phenyl)-3-(6-methyl-1,1-dioxo-1-thiochroman-7-sulfonyl)-urea

6-Methyl-1,1-dioxo-1-thiochroman-7-sulfonamide; 2,6-Diisopropyl-phenyl
isocyanate. mp: 242.7-245.2°C.

EXAMPLE 47

1-(2,6-Diisopropyl-phenyl)-3-[3-(1-hydroxy-ethyl)-benzenesulfonyl]-urea

3-(1-Hydroxy-ethyl)-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 122.6-124.0°C.

5

EXAMPLE 48

1-(4-Bromo-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-ethyl)-benzenesulfonyl]-urea

3-(1-Hydroxy-ethyl)-benzenesulfonamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp: 142.5-144.8°C.

EXAMPLE 49

10 1-(3-Acetyl-benzenesulfonyl)-3-(4-bromo-2,6-diisopropyl-phenyl)-urea

3-Acetyl-benzenesulfonamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp: 231.4-233.6°C.

EXAMPLE 50

1-(3-Acetyl-4-hydroxy-benzenesulfonyl)-3-(2,6-diisopropyl-phenyl)-urea

15 3-Acetyl-4-hydroxy-benzenesulfonamide; 2,6-Diisopropyl-phenylisocyanate. mp: 196.6-198.9°C.

EXAMPLE 51

1-(3-Acetyl-4-methoxy-benzenesulfonyl)-3-(2,6-diisopropyl-phenyl)-urea

20 3-Acetyl-4-methoxy-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 203.4-205.7°C.

EXAMPLE 52

1-(3-Acetyl-benzenesulfonyl)-3-(2-sec-butyl-6-ethyl-phenyl)-urea

3-Acetyl-benzenesulfonamide; 2-sec-Butyl-6-ethyl-phenylisocyanate. mp: 136.3-138.9°C.

25

EXAMPLE 53

1-(3-Acetyl-benzenesulfonyl)-3-(2-isopropyl-6-methyl-phenyl)-urea

3-Acetyl-benzenesulfonamide; 2-Isopropyl-6-methyl-phenyl isocyanate. mp: 136.8-138.9°C.

EXAMPLE 54

30 1-(3-Acetyl-benzenesulfonyl)-3-(2-tert-butyl-6-methyl-phenyl)-urea

3-Acetyl-benzenesulfonamide; 2-tert-Butyl-6-methyl-phenyl isocyanate. mp: 155.4-157.7°C.

-50-

EXAMPLE 551-(3-Acetyl-benzenesulfonyl)-3-(2-ethyl-6-isopropyl-phenyl)-urea

3-Acetyl-benzenesulfonamide; 2-Ethyl-6-isopropyl-phenyl isocyanate. mp: 127.1-128.5°C.

5

EXAMPLE 561-(3-Acetyl-benzenesulfonyl)-3-(2,6-diisopropyl-phenyl)-urea

3-Acetyl-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 151.6-153.5°C.

EXAMPLE 5710 1-(4-Acetyl-2,6-diisopropyl-phenyl)-3-(3,5-diacetyl-benzenesulfonyl)-urea

3,5-Diacetyl-benzenesulfonamide; 4-Acetyl-2,6-diisopropyl-phenyl isocyanate. mp: 154.0-156.4°C.

EXAMPLE 58

4-[3-(3,5-Diacetyl-benzenesulfonyl)-ureido]-3,5-diisopropyl-benzamide

15 3,5-Diacetyl-benzenesulfonamide; 4-Isocyanato-3,5-diisopropyl-benzamide. mp: 198.5-199.8°C.

EXAMPLE 591-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(2,2,2-trifluoro-1-hydroxy-ethyl)-benzenesulfonyl]-urea

20 3-(2,2,2-Trifluoro-1-hydroxy-ethyl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 129.6-131.5°C.

EXAMPLE 601-(4-Chloro-2,6-diisopropyl-phenyl)-3-(3-trifluoroacetyl-benzenesulfonyl)-urea

25 3-Trifluoroacetyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 88.4-89.1°C.

EXAMPLE 611-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-2-methoxy-ethyl)-benzenesulfonyl]-urea

30 3-(1-Hydroxy-2-methoxy-ethyl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 108.7-109.2°C.

-51-

EXAMPLE 621-(4-Chloro-2,6-diisopropyl-phenyl)-3-(3-methoxyacetyl-benzenesulfonyl)-urea

3-Methoxyacetyl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 121.2-122.1°C.

5

EXAMPLE 634-[3-[3-(1-Hydroxy-ethyl)-benzenesulfonyl]-ureido]-3,5-diisopropyl-benzamide

3-(1-Hydroxy-ethyl)-benzenesulfonamide; 4-Isocyanato-3,5-diisopropyl-benzamide. mp: 204.6-205.9°C.

EXAMPLE 6410 1-(4-Cyano-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-ethyl)-benzenesulfonyl]-urea

3-(1-Hydroxy-ethyl)-benzenesulfonamide; 4-Cyano-2,6-diisopropyl-phenyl isocyanate. mp: 191.3-194.0°C.

EXAMPLE 6515 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-2-methyl-propyl)-benzenesulfonyl]-urea

3-(1-Hydroxy-2-methyl-propyl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 152.3-153.0°C.

EXAMPLE 661-(4-Chloro-2,6-diisopropyl-phenyl)-3-(3-isobutyryl-benzenesulfonyl)-urea20

3-Isobutyryl-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 170.2-171.4°C.

EXAMPLE 671-(2,6-Diisopropyl-4-thiophen-3-yl-phenyl)-3-[3-(1-hydroxy-ethyl)-benzenesulfonyl]-urea25

3-(1-Hydroxy-ethyl)-benzenesulfonamide; 2,6-Diisopropyl-4-thiophen-3-yl-phenyl isocyanate. mp: 137.0-139.4°C.

EXAMPLE 681-(2,6-Diisopropyl-4-thiophen-2-yl-phenyl)-3-[3-(1-hydroxy-ethyl)-benzenesulfonyl]-urea

3-(1-Hydroxy-ethyl)-benzenesulfonamide; 2,6-Diisopropyl-4-thiophen-2-yl-phenyl isocyanate. mp: 98.4-99.9°C.

30

EXAMPLE 691-(3,5-Diisopropyl-biphenyl-4-yl)-3-[3-(1-hydroxy-ethyl)-benzenesulfonyl]-urea

3-(1-Hydroxy-ethyl)-benzenesulfonamide; 4-Isocyanato-3,5-diisopropyl-biphenyl. mp: 127.4-128.6°C.

-52-

EXAMPLE 70

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-(8-hydroxy-5,6,7,8-tetrahydro-naphthalene-2-sulfonyl)-urea

8-Hydroxy-5,6,7,8-tetrahydro-naphthalene-2-sulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 136.8-138.2°C.

EXAMPLE 71

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-(8-oxo-5,6,7,8-tetrahydro-naphthalene-2-sulfonyl)-urea

8-Oxo-5,6,7,8-tetrahydro-naphthalene-2-sulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 180.0-182.4°C.

EXAMPLE 72

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-(8-hydroxyimino-5,6,7,8-tetrahydro-naphthalene-2-sulfonyl)-urea

8-Hydroxyimino-5,6,7,8-tetrahydro-naphthalene-2-sulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 162.5-164.2°C.

EXAMPLE 73

1-(4-Bromo-2,6-diisopropyl-phenyl)-3-(8-hydroxy-5,6,7,8-tetrahydro-naphthalene-2-sulfonyl)-urea

8-Hydroxy-5,6,7,8-tetrahydro-naphthalene-2-sulfonamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp: 164.0-165.8°C.

EXAMPLE 74

1-(2,6-Diisopropyl-phenyl)-3-(8-hydroxy-5,6,7,8-tetrahydro-naphthalene-2-sulfonyl)-urea

8-Hydroxy-5,6,7,8-tetrahydro-naphthalene-2-sulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 120.0-122.6°C.

EXAMPLE 75

1-(2,6-Diisopropyl-phenyl)-3-(8-hydroxyimino-5,6,7,8-tetrahydro-naphthalene-2-sulfonyl)-urea

8-Hydroxyimino-5,6,7,8-tetrahydro-naphthalene-2-sulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 139.2-140.0°C.

30

-53-

EXAMPLE 76

1-(4-Bromo-2,6-diisopropyl-phenyl)-3-(8-hydroxyimino-5,6,7,8-tetrahydro-naphthalene-2-sulfonyl)-urea

8-Hydroxyimino-5,6,7,8-tetrahydro-naphthalene-2-sulfonamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp: 168.6-169.2°C.

EXAMPLE 77

1-(4-Bromo-2,6-diisopropyl-phenyl)-3-(8-oxo-5,6,7,8-tetrahydro-naphthalene-2-sulfonyl)-urea

8-Oxo-5,6,7,8-tetrahydro-naphthalene-2-sulfonamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp: 208.0-208.8°C.

EXAMPLE 78

1-(2,6-Diisopropyl-phenyl)-3-(8-oxo-5,6,7,8-tetrahydro-naphthalene-2-sulfonyl)-urea

8-Oxo-5,6,7,8-tetrahydro-naphthalene-2-sulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 197.4-198.0°C.

EXAMPLE 79

3-[3-(4-Bromo-2,6-diisopropyl-phenyl)-ureidosulfonyl]-benzamide

3-Sulfonamido-benzamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp: 180.0-180.6°C.

EXAMPLE 80

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1,2-dihydroxy-ethyl)-benzenesulfonyl]-urea

3-(1,2-Dihydroxy-ethyl)-benzenesulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 169.7-171.2°C.

EXAMPLE 81

3-[3-(2,6-Diisopropyl-phenyl)-ureidosulfonyl]-benzamide

3-Sulfonamido-benzamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 182.3-184.1°C.

EXAMPLE 82

3-[3-(4-Bromo-2,6-diisopropyl-phenyl)-ureidosulfonyl]-N-methyl-benzamide

3-Sulfonamido-N-methyl-benzamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp: 243.8-245.1°C.

-54-

EXAMPLE 833-[3-(2,6-Diisopropyl-phenyl)-ureidosulfonyl]-N-methyl-benzamide

3-Sulfonamido-N-methyl-benzamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 236.2-237.2°C.

5

EXAMPLE 841-(5-Acetyl-2-bromo-benzenesulfonyl)-3-(4-bromo-2,6-diisopropyl-phenyl)-urea

5-Acetyl-2-bromo-benzenesulfonamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp: 177.2-179.1°C.

EXAMPLE 8510 1-[2-Chloro-5-(1-hydroxy-ethyl)-benzenesulfonyl]-3-(2,6-diisopropyl-phenyl)-urea

2-Chloro-5-(1-hydroxy-ethyl)-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 154.0-156.0°C.

EXAMPLE 8615 1-[2-Chloro-5-(1-hydroxy-ethyl)-benzenesulfonyl]-3-(4-bromo-2,6-diisopropyl-phenyl)-urea

2-Chloro-5-(1-hydroxy-ethyl)-benzenesulfonamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp: 144.3-146.2°C.

EXAMPLE 8720 1-[2-Chloro-5-(1-hydroxyimino-ethyl)-benzenesulfonyl]-3-(2,6-diisopropyl-phenyl)-urea

2-Chloro-5-(1-hydroxyimino-ethyl)-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 156.6-158.0°C.

EXAMPLE 8825 1-[2-Chloro-5-(1-hydroxyimino-ethyl)-benzenesulfonyl]-3-(4-bromo-2,6-diisopropyl-phenyl)-urea

2-Chloro-5-(1-hydroxyimino-ethyl)-benzenesulfonamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp: 185.0-186.2°C.

EXAMPLE 8930 1-(5-Acetyl-2-chloro-benzenesulfonyl)-3-(2,6-diisopropyl-phenyl)-urea

5-Acetyl-2-chloro-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp 180.7-182.3°C.

EXAMPLE 901-(5-Acetyl-2-chloro-benzenesulfonyl)-3-(4-bromo-2,6-diisopropyl-phenyl)-urea

5-Acetyl-2-chloro-benzenesulfonamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp: 175.2-176.5°C.

-55-

EXAMPLE 913-[3-(2,6-Diisopropyl-phenyl)-ureidosulfonyl]-N,N-dimethyl-benzamide

3-Sulfonamido-N,N-dimethyl-benzamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 211.8-212.6°C.

5

EXAMPLE 923-[3-(4-Bromo-2,6-diisopropyl-phenyl)-ureidosulfonyl]-N,N-dimethyl-benzamide

3-Sulfonamido-N,N-dimethyl-benzamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp: 225.7-227.6°C.

EXAMPLE 9310 1-(2,6-Diisopropyl-phenyl)-3-(3-formyl-benzenesulfonyl)-urea

3-Formyl-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 108.3-109.0°C.

EXAMPLE 941-(2,6-Diisopropyl(hydroxyimino-methyl)-benzenesulfonyl)-urea

15 3-(Hydroxyimino-methyl)-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 107.0-108.1°C.

EXAMPLE 951-(2,6-Diisopropyl-phenyl)-3-[3-(1-methoxyimino-ethyl)-benzenesulfonyl]-urea

20 3-(1-Methoxyimino-ethyl)-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 164.9-165.9°C.

EXAMPLE 961-[3-(1-Benzyloxyimino-ethyl)-benzenesulfonyl]-3-(2,6-diisopropyl-phenyl)-urea

25 3-(1-Benzyloxyimino-ethyl)-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 136.5-139.0°C.

EXAMPLE 971-(2,6-Diisopropyl-phenyl)-3-[3-(1-ethoxyimino-ethyl)-benzenesulfonyl]-urea

30 3-(1-Ethoxyimino-ethyl)-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 156.9-158.4°C.

EXAMPLE 981-{3-[3-(2,6-Diisopropyl-phenyl)-ureidosulfonyl]-phenyl}-ethylideneaminooxy)-acetic acid

3-Sulfonamido-phenyl-(1-ethylideneaminooxy)-acetic acid; 2,6-Diisopropyl-phenyl isocyanate. mp: 107.1-107.7°C.

-56-

EXAMPLE 991-(2,6-Diisopropyl-phenyl)-3-[3-(1-hydroxyimino-ethyl)-benzenesulfonyl]-urea

3-(1-Hydroxyimino-ethyl)-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate.
mp: 131.0-132.6°C.

5

EXAMPLE 1001-(2,6-Diisopropyl-phenyl)-3-(3-methanesulfonyl-benzenesulfonyl)-urea

3-Methanesulfonyl-benzenesulfonamide; 2,6-Diisopropyl-phenylisocyanate. mp:
99.5-100.6°C.

EXAMPLE 10110 1-(2,6-Diisopropyl-phenyl)-3-(3-methanesulfinyl-benzenesulfonyl)-urea

3-Methanesulfinyl-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate.
mp: 217.4-221.0°C.

EXAMPLE 1023-[3-(2,6-Diisopropyl-phenyl)-ureidosulfonyl]-benzenesulfonamide15

3-Sulfonamido-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp:
131.4-133.5°C.

EXAMPLE 1031-(4-Bromo-2,6-diisopropyl-phenyl)-3-(3-formyl-benzenesulfonyl)-urea20

3-Formyl-benzenesulfonamide; 4-Bromo-2,6-diisopropyl-phenyl isocyanate. mp:
127.2-128.6°C.

EXAMPLE 1041-[3-(2-Acetyl-phenoxyethyl)-benzenesulfonyl]-3-(2,6-diisopropyl-phenyl)-urea

3-(2-Acetyl-phenoxyethyl)-benzenesulfonamide; 2,6-Diisopropyl-phenyl
isocyanate. mp: 124.2-125°C.

25

EXAMPLE 1051-[3-(1-Amino-ethyl)-benzenesulfonyl]-3-(2,6-diisopropyl-phenyl)-urea hydrochloride

3-(1-Amino-ethyl)-benzenesulfonamide hydrochloride; 2,6-Diisopropyl-phenyl
isocyanate. mp: 210.6-212.9°C.

30

EXAMPLE 1061-(2,6-Diisopropyl-phenyl)-3-(3-furan-2-yl-benzenesulfonyl)-urea

3-Furan-2-yl-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp:
196.6-198.0°C.

-57-

EXAMPLE 1071-(2,6-Diisopropyl-phenyl)-3-(4-furan-2-yl-benzenesulfonyl)-urea

4-Furan-2-yl-benzenesulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 201.5-202.7°C.

5

EXAMPLE 1081-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxyimino-ethyl)-thiophene-2-sulfonyl]-urea

4-(1-Hydroxyimino-ethyl)-thiophene-2-sulfonamide; 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene. mp: 261.8-266.1°C.

10

EXAMPLE 1091-(4-Acetyl-thiophene-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea

4-Acetyl-thiophene-2-sulfonamide; 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene. mp: 270.2-272.3°C.

EXAMPLE 110

15 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[5-(1-hydroxy-1-methyl-ethyl)-thiophene-3-sulfonyl]-urea

5-(1-Hydroxy-1-methyl-ethyl)-thiophene-3-sulfonamide; 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene. mp: 149.5-154.8°C.

EXAMPLE 111

20 1-(2,6-Diisopropyl-phenyl)-3-[4-(1-hydroxy-1-methyl-ethyl)-thiophene-2-sulfonyl]-urea

4-(1-Hydroxy-1-methyl-ethyl)-thiophene-2-sulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp = 124.6-127.4°C.

EXAMPLE 1121-(2,6-Diisopropyl-phenyl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea

25 4-(1-Hydroxy-1-methyl-ethyl)-furan-2-sulfonamide; 2,6-Diisopropyl-phenyl isocyanate. mp: 121.3-126.4°C.

-58-

EXAMPLE 113

1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-thiophene-2-sulfonyl]-urea

4-(1-Hydroxy-1-methyl-ethyl)-thiophene-2-sulfonamide; 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene. mp: 133.1-134.0°C.

EXAMPLE 114

1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea

4-(1-Hydroxy-1-methyl-ethyl)-furan-2-sulfonamide; 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene. mp: 153.8-154.4°C.

EXAMPLE 115

1-(8-Chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea

4-(1-Hydroxy-1-methyl-ethyl)-furan-2-sulfonamide; 4-Chloro-8-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene. mp: 163.7°C (decomposed).

EXAMPLE 116

1-(4-Formyl-furan-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea

4-Formyl-furan-2-sulfonamide; 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene. mp: 281.3-284.1°C.

EXAMPLE 117

1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-(4-hydroxymethyl-thiophene-2-sulfonyl)-urea

4-Hydroxymethyl-thiophene-2-sulfonamide; 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene. mp: 273.9-275.8°C.

EXAMPLE 118

1-(4-Formyl-thiophene-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea

4-Formyl-thiophene-2-sulfonamide; 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene. mp: 146.3-148.9°C.

EXAMPLE 119

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[4-(1-hydroxyimino-ethyl)-thiophene-2-sulfonyl]-urea

4-(1-Hydroxyimino-ethyl)-thiophene-2-sulfonamide; 4-Chloro-2,6-diisopropyl-phenyl isocyanate. mp: 184.7-187.8°C.

EXAMPLE 120

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[5-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea
5-(1-Hydroxy-1-methyl-ethyl)-furan-2-sulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 116.0-117.9°C.

5

EXAMPLE 121

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea
4-(1-Hydroxy-1-methyl-ethyl)-furan-2-sulfonamide; 4-Chloro-2,6-diisopropyl-phenyl
isocyanate. mp: 127.4-129.2°C.

EXAMPLE 122

10 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[4-(1-hydroxy-1-methyl-ethyl)-thiophene-2-sulfonyl]-
urea
4-(1-Hydroxy-1-methyl-ethyl)-thiophene-2-sulfonamide; 4-Chloro-2,6-diisopropyl-
phenyl isocyanate. mp: 131.2-133.6°C.

EXAMPLE 123

15 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[5-(1-hydroxy-1-methyl-ethyl)-thiophene-2-sulfonyl]-
urea, sodium salt
5-(1-Hydroxy-1-methyl-ethyl)-thiophene-2-sulfonamide; 4-Chloro-2,6-diisopropyl-
phenyl isocyanate. mp: 270.3-271.9°C.

EXAMPLE 124

20 1-(4-[1,3]Dioxolan-2-yl-thiophene-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-
urea
4-[1,3]Dioxolan-2-yl-thiophene-2-sulfonamide; 4-Isocyanato-1,2,3,5,6,7-
hexahydro-s-indacene. mp: 224.7-226.6°C.

EXAMPLE 125

25 1-(4-[1,3]Dioxolan-2-yl-furan-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea
4-[1,3]Dioxolan-2-yl-furan-2-sulfonamide; 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-
indacene. mp: 183.5°C (decomposition).

-60-

EXAMPLE 126

1-[3-(4,5-Dihydro-1H-imidazol-2-yl)-benzenesulfonyl]-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea

3-(4,5-Dihydro-1H-imidazol-2-yl)-benzenesulfonamide; 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene. mp: 241.0°C (decomposition).

EXAMPLE 127

1-(1H-Benzoimidazole-5-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea

1H-Benzoimidazole-5-sulfonamide; 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene. mp: 239.0°C (decomposition).

EXAMPLE 128

1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[3-(1-hydroxyimino-ethyl)-benzenesulfonyl]-urea

3-(1-Hydroxyimino-ethyl)-benzenesulfonamide; 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene. mp: 249.8°C (decomposition).

EXAMPLE 129

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-tert-butylsulfamoyl-benzenesulfonyl]urea

Benzene-1,3-disulfonic acid amide tert-butyl-amide; 5-Chloro-2-isocyanto-1,3-diisopropyl-benzene.

EXAMPLE 130


1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-sulfamoyl-benzenesulfonyl]-urea

Using a procedure similar to that of Preparation G, from 200 mg (0.38 mmole) of 1-(4-chloro-2,6-diisopropyl-phenyl)-3-[3-tert-butylsulfamoyl-benzenesulfonyl]-urea, there was obtained 92 mg of the titled compound as a white solid. mp: 172-177°C.

-61-

CLAIMS

1. A compound of the formula




or a pharmaceutically acceptable salt thereof, wherein

R¹ is (C₁-C₆)alkyl optionally substituted by (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, trifluoromethyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy, (C₅-C₉)heteroarylamino, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroaryloxy, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₆)cycloalkyl, hydroxy(C₁-C₆)alkyl, (C₁-C₆)alkyl(hydroxymethylene), piperazinyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy, (C₅-C₉)heteroaryl(C₁-C₆)alkoxy, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, (C₁-C₆)alkylsulfinyl, (C₆-C₁₀)arylsulfinyl, (C₁-C₆)alkylsulfonyl, (C₆-C₁₀)arylsulfonyl, amino, (C₁-C₆)alkylamino or

15 ((C₁-C₆)alkyl)₂amino; or

R¹ and R² are each independently a group of the formula



wherein the broken lines represent optional double bonds;

n is 0, 1, 2 or 3;


25 A, B, D, E and G are each independently oxygen, sulfur, nitrogen or CR⁵R⁶ wherein R⁵ and R⁶ are each independently selected from hydrogen, (C₁-C₆)alkyl optionally substituted by one or two groups selected from (C₁-C₆)alkylamino, (C₁-C₆)alkylthio, (C₁-C₆)alkoxy, hydroxy, cyano, perfluoro(C₁-C₆)alkyl, (C₆-C₁₀)aryl, (C₅-C₉)heteroaryl, (C₆-C₁₀)arylamino, (C₆-C₁₀)arylthio, (C₆-C₁₀)aryloxy wherein the aryl group

30 is optionally substituted by (C₁-C₆)alkoxy, (C₁-C₆)acyl, carboxy, hydroxy or halo; (C₅-C₉)heteroarylamino, (C₅-C₉)heteroarylthio, (C₅-C₉)heteroaryloxy, (C₆-C₁₀)aryl(C₆-C₁₀)aryl, (C₃-C₆)cycloalkyl, hydroxy, piperazinyl, (C₆-C₁₀)aryl(C₁-C₆)alkoxy, (C₅-C₉)heteroaryl(C₁-C₆)alkoxy, (C₁-C₆)acylamino, (C₁-C₆)acylthio, (C₁-C₆)acyloxy, (C₁-C₆)alkylsulfinyl, (C₆-

-62-

C_{10})arylsulfinyl, (C_1-C_6) alkylsulfonyl, (C_6-C_{10}) arylsulfonyl, amino, (C_1-C_6) alkylamino or $((C_1-C_6)alkyl)_2$ amino; halo, cyano, amino, hydroxy, perfluoro (C_1-C_6) alkyl, perfluoro (C_1-C_6) alkoxy, (C_2-C_6) alkenyl, carboxy (C_2-C_6) alkenyl, (C_2-C_6) alkynyl, (C_1-C_6) alkylamino, $((C_1-C_6)alkyl)_2$ amino, (C_1-C_6) alkylsulfonylamido, (C_1-C_6) alkylsulfinyl, aminosulfonyl, (C_1-C_6) alkylaminosulfonyl, $((C_1-C_6)alkyl)_2$ aminosulfonyl, (C_1-C_6) alkylthio, (C_1-C_6) alkoxy, perfluoro (C_1-C_6) alkyl, (C_6-C_{10}) aryl, (C_5-C_9) heteroaryl, (C_6-C_{10}) arylamino, (C_6-C_{10}) arylthio, (C_6-C_{10}) aryl (C_1-C_6) alkoxy, (C_5-C_9) heteroarylamino, (C_5-C_9) heteroarylthio, (C_5-C_9) heteroaryloxy, (C_3-C_6) cycloalkyl, (C_1-C_6) alkyl(hydroxymethylene), piperidyl, pyridinyl, thienyl, furanyl, (C_1-C_6) alkylpiperidyl, (C_1-C_6) acylamino, (C_1-C_6) acylthio, (C_1-C_6) acyloxy, $R^7(C_1-C_6)alkyl$ wherein R^7 is (C_1-C_6) acylpiperazino, (C_6-C_{10}) arylpiperazino, (C_5-C_9) heteroarylpiperazino, (C_1-C_6) alkylpiperazino, (C_6-C_{10}) aryl (C_1-C_6) alkylpiperazino, (C_5-C_9) heteroaryl (C_1-C_6) alkylpiperazino, morpholino, thiomorpholino, piperidino, pyrrolidino, piperidyl, (C_1-C_6) alkylpiperidyl, (C_6-C_{10}) arylpiperidyl, (C_5-C_9) heteroarylpiperidyl, $(C_1-C_6)alkylpiperidyl(C_1-C_6)alkyl$, $(C_6-C_{10})arylpiperidyl(C_1-C_6)alkyl$, $(C_5-C_9)heteroarylpiperidyl(C_1-C_6)alkyl$ or $(C_1-C_6)acylpiperidyl$;

or a group of the formula



wherein s is 0 to 6;

t is 0 or 1;


X is oxygen or NR^8 wherein R^8 is hydrogen, $(C_1-C_6)alkyl$ or $(C_3-C_7)cycloalkyl(C_1-C_6)alkyl$;

Y is hydrogen, hydroxy, $(C_1-C_6)alkyl$, optionally substituted by halo, hydroxy or cyano; $(C_1-C_6)alkoxy$, cyano, $(C_2-C_6)alkynyl$, $(C_6-C_{10})aryl$ wherein the aryl group is optionally substituted by halo, hydroxy, carboxy, $(C_1-C_6)alkyl$, $(C_1-C_6)alkoxy$; perfluoro $(C_1-C_6)alkyl$, $(C_1-C_6)alkoxy(C_1-C_6)alkyl$ or NR^9R^{10} wherein R^9 and R^{10} are each independently selected from the group consisting of hydrogen, $(C_1-C_6)alkyl$ optionally substituted by $(C_1-C_6)alkylpiperidyl$, $(C_6-C_{10})arylpiperidyl$, $(C_5-C_9)heteroarylpiperidyl$, $(C_6-$

-63-

C_{10})aryl, (C_5-C_9) heteroaryl or (C_3-C_6) cycloalkyl; piperidyl, (C_1-C_6) alkylpiperidyl, (C_6-C_{10}) arylpiperidyl, (C_5-C_9) heteroarylpiperidyl, (C_1-C_6) acylpiperidyl, (C_6-C_{10}) aryl, (C_5-C_9) heteroaryl, (C_3-C_6) cycloalkyl, $R^{11}(C_2-C_6)$ alkyl, (C_1-C_5) alkyl(CHR¹¹)(C₁-C₆)alkyl wherein R¹¹ is hydroxy, (C₁-C₆)acyloxy, (C₁-C₆)alkoxy, piperazino, (C₁-C₆)acylamino, (C₁-C₆)alkylthio, (C₆-C₁₀)arylthio, (C₁-C₆)alkylsulfinyl, (C₆-C₁₀)arylsulfinyl, (C₁-C₆)alkylsulfoxyl, (C₆-C₁₀)arylsulfoxyl, amino, (C₁-C₆)alkylamino, ((C₁-C₆)alkyl)₂amino, (C₁-C₆)acylpiperazino, (C₁-C₆)alkylpiperazino, (C₆-C₁₀)aryl(C₁-C₆)alkylpiperazino, (C₅-C₉)heteroaryl(C₁-C₆)alkylpiperazino, morpholino, thiomorpholino, piperidino or pyrrolidino; R¹²(C₁-C₆)alkyl, (C₁-C₅)alkyl(CHR¹²)(C₁-C₆)alkyl wherein R¹² is piperidyl or (C₁-C₆)alkylpiperidyl; and CH(R¹³)COR¹⁴ wherein R¹⁴ is as defined below and R¹³ is hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl, (C₅-C₉)heteroaryl(C₁-C₆)alkyl, (C₁-C₆)alkylthio(C₁-C₆)alkyl, (C₆-C₁₀)arylthio(C₁-C₆)alkyl, (C₁-C₆)alkylsulfinyl(C₁-C₆)alkyl, (C₆-C₁₀)arylsulfinyl(C₁-C₆)alkyl, (C₁-C₆)alkylsulfonyl(C₁-C₆)alkyl, (C₆-C₁₀)arylsulfonyl(C₁-C₆)alkyl, hydroxy(C₁-C₆)alkyl, amino(C₁-C₆)alkyl, (C₁-C₆)alkylamino(C₁-C₆)alkyl, ((C₁-C₆)alkylamino)₂(C₁-C₆)alkyl, R¹⁵R¹⁶NCO(C₁-C₆)alkyl or R¹⁵OCO(C₁-C₆)alkyl wherein R¹⁵ and R¹⁶ are each independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl and (C₅-C₉)heteroaryl(C₁-C₆)alkyl; and R¹⁴ is R¹⁷O or R¹⁷R¹⁸N wherein R¹⁷ and R¹⁸ are each independently selected from the group consisting of hydrogen, (C₁-C₆)alkyl, (C₆-C₁₀)aryl(C₁-C₆)alkyl and (C₅-C₉)heteroaryl(C₁-C₆)alkyl;

or a group of the formula




wherein u is 0, 1 or 2;

R¹⁹ is hydrogen, (C₁-C₆)alkyl or perfluoro(C₁-C₆)alkyl;

R²⁰ is hydrogen, (C₁-C₆)alkyl, (C₁-C₆)carboxyalkyl or (C₆-C₁₀)aryl(C₁-C₆)alkyl;

or a group of the formula

-64-



10 wherein a is 0, 1 or 2;

b is 0 or 1;

c is 1, 2 or 3;

d is 0 or 1;


e is 0, 1 or 2;

15 J and L are each independently oxygen or sulfur;

R^{21} is hydrogen, hydroxy, fluoro, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, halo (C_1-C_6) alkyl, amino, (C_1-C_6) acylamino or $NR^{26}R^{27}$ wherein R^{26} and R^{27} are each independently selected from hydrogen, (C_1-C_6) alkyl or (C_6-C_{10}) aryl; and

20 R^{22} is hydrogen, (C_1-C_6) alkyl optionally substituted by hydroxy, halo, (C_1-C_6) alkylthio, (C_1-C_6) alkylsulfinyl or (C_1-C_6) alkylsulfonyl;

or when n is 1 and B and D are both CR^5 , the two R^5 groups may be taken together with the carbons to which they are attached to form a group of the formula



wherein the broken lines represent optional double bonds;


30 m is 0 or 1; and

T, U, V and W are each independently oxygen, sulfur, CO, nitrogen or CR^5R^6 wherein R^5 and R^6 are as defined above;

-65-

or when A and B, or when n is 1 and B and D, or D and E, or E and G, are both CR⁵, the two R⁵ groups may be taken together with the adjacent carbons to which they are attached to form a (C₅-C₆)cycloalkyl group optionally substituted by hydroxy or a benzo group;

5 or when n is 1 and D and E are both CR⁵, the two R⁵ groups may be taken together with the adjacent carbons to which they are attached to form a group of the formula



15

wherein the broken line represents an optional double bond;

R²³ is hydrogen, (C₁-C₆)alkyl, halo, amino or (C₁-C₆)alkoxy;

J is C or SO;

20 K is oxygen, NR²⁴ wherein R²⁴ is hydroxy, (C₁-C₆)alkoxy or (C₆-C₁₀)aryl(C₁-C₆)alkoxy; or hydroxy;

or R²⁵SO₂ wherein R²⁵ is defined as R¹ above or (C₃-C₇)cycloalkylamino; and

with the proviso that the groups of formulas II and VI cannot have two oxygens, two sulfurs or an oxygen and sulfur defined in adjacent positions;

with the proviso that R² must be aromatic;

25 with the proviso that when either a or e is 0, the other must be 1;


with the proviso that when b and d are 1, the sum of a, c and e cannot be 6 or 7; and

with the proviso that when A, B, D, E, G, T, U, V and W represent an sp² carbon, R⁶ does not exist.

30 2. A compound according to claim 1, wherein R¹ is a group of the formula

-66-

5



wherein the broken lines represent double bonds;


10

n is 0 or 1;

A is CR^5 wherein R^5 is hydrogen or halo;

B and E are both independently CR^5 wherein R^5 is hydrogen cyano, halo, (C_1-C_6) alkyl optionally substituted by one or two hydroxy; (C_3-C_7) cycloalkylaminosulfonyl, (C_1-C_6) alkylaminosulfonyl, or a group of the formula

15



20

wherein s is 0;

t is 0; and

Y is hydrogen, (C_1-C_6) alkyl optionally substituted by halo; or (C_1-C_6) alkoxy $(C_1-$

25


$C_6)$ alkyl;

or a group of the formula

30

-67-

5



10 wherein a is 0 or 1;

b is 0 or 1;

c is 1 or 2;

d is 0 or 1;


e is 0 or 1;

15 J and L are each independently oxygen or sulfur;

R²¹ is hydrogen, hydroxy or (C₁-C₆)alkyl optionally substituted by halo; andR²² is hydrogen or (C₁-C₆)alkyl optionally substituted by hydroxy, halo, (C₁-C₆)alkylthio, (C₁-C₆)alkylsulfinyl or (C₁-C₆)alkylsulfonyl;

or a group of the formula


20



25 wherein u is 0 or 1;

R¹⁹ is (C₁-C₆)alkyl or trifluoromethyl; andR²⁰ is hydrogen;D is CR⁵ wherein R⁵ is hydrogen, (C₁-C₆)alkyl or halo;G is CR⁵ wherein R⁵ is oxygen, sulfur or CR⁵ wherein R⁵ is hydrogen or halo;30 or when n is 1 and B and D are both CR⁵, the two R⁵ groups may be taken together with the carbons to which they are attached to form a group of the formula

-68-



wherein the broken lines represent double bonds;


m is 0;

T is oxygen, nitrogen or CR⁵ wherein R⁵ is hydrogen;

U is CO or CR⁵ wherein R⁵ is hydrogen; and

W is nitrogen or CR⁵ wherein R⁵ is hydrogen;

or when n is 1 and D and E are both CR⁵, the two R⁵ groups may be taken together with the adjacent carbons to which they are attached to form a group of the formula




wherein the broken line represents an optional double bond;

R²³ is hydrogen or (C₁-C₆)alkyl;

J is C or SO

K is oxygen, NR²⁴ wherein R²⁴ is hydroxy; or hydroxy.

3. A compound according to claim 1, wherein R² is a group of the formula



-69-


wherein the broken lines represent optional double bonds;

n is 1;

A is CR^5 wherein R^5 is halo or $(\text{C}_1\text{-C}_6)\text{alkyl}$;

B is CR^5 wherein R^5 is hydrogen or halo;

5 D is CR^5 wherein R^5 is hydrogen, halo, cyano or a group of the formula



wherein s is 0;

t is 0; and

15 Y is NH_2 ;


E is CR^5 wherein R^5 is hydrogen or halo; and

G is CR^5 wherein R^5 is halo or $(\text{C}_1\text{-C}_6)\text{alkyl}$;

or when A and B, or E and G, are both CR^5 , the two R^5 groups may be taken together with the adjacent carbons to which they are attached to form a $(\text{C}_5\text{-C}_6)$ cycloalkyl group.

20

4. A compound according to claim 1, wherein R^1 is a group of the formula




30 wherein the broken lines represent double bonds;

n is 0 is 1;

A is CR^5 wherein R^5 is hydrogen or halo;

-70-

B and E are both independently CR^5 wherein R^5 is hydrogen cyano, halo, $(\text{C}_1\text{-C}_6)$ alkyl optionally substituted by one or two hydroxy; $(\text{C}_3\text{-C}_7)$ cycloalkylaminosulfonyl, $(\text{C}_1\text{-C}_6)$ alkylaminosulfonyl, or a group of the formula




wherein s is 0;

t is 0; and

Y is hydrogen, $(\text{C}_1\text{-C}_6)$ alkyl optionally substituted by halo; or $(\text{C}_1\text{-C}_6)$ alkoxy $(\text{C}_1\text{-C}_6)$ alkyl;

15 or a group of the formula



25 wherein a is 0 or 1;

b is 0 or 1;

c is 1 or 2;

d is 0 or 1;

e is 0 or 1;


30 J and L are each independently oxygen or sulfur;

R^{21} is hydrogen, hydroxy or $(\text{C}_1\text{-C}_6)$ alkyl optionally substituted by halo; and

R^{22} is hydrogen or $(\text{C}_1\text{-C}_6)$ alkyl optionally substituted by hydroxy, halo, $(\text{C}_1\text{-C}_6)$ alkylthio, $(\text{C}_1\text{-C}_6)$ alkylsulfinyl or $(\text{C}_1\text{-C}_6)$ alkylsulfonyl;

-71-

or a group of the formula



wherein u is 0 or 1;


R¹⁹ is (C₁-C₆)alkyl or trifluoromethyl; and

R²⁰ is hydrogen;

10 D is CR⁵ wherein R⁵ is hydrogen, (C₁-C₆)alkyl or halo;

G is CR⁵ wherein R⁵ is oxygen, sulfur or CR⁵ wherein R⁵ is hydrogen or halo;

or when n is 1 and B and D are both CR⁵, the two R⁵ groups may be taken together with the carbons to which they are attached to form a group of the formula



20 wherein the broken lines represent double bonds;

m is 0;

T is oxygen, nitrogen or CR⁵ wherein R⁵ is hydrogen;

U is CO or CR⁵ wherein R⁵ is hydrogen; and


W is nitrogen or CR⁵ wherein R⁵ is hydrogen;

25 or when n is 1 and D and E are both CR⁵, the two R⁵ groups may be taken together with the adjacent carbons to which they are attached to form a group of the formula

30

-72-

5



wherein the broken line represents an optional double bond;

10


R^{23} is hydrogen or (C_1-C_6) alkyl;

J is C or SO

K is oxygen, NR^{24} wherein R^{24} is hydroxy; or hydroxy; and

R^2 is a group of the formula

15



20

wherein the broken lines represent optional double bonds;


n is 1;

A is CR^5 wherein R^5 is halo or (C_1-C_6) alkyl;

B is CR^5 wherein R^5 is hydrogen or halo;

D is CR^5 wherein R^5 is hydrogen, halo, cyano or a group of the formula

25



30

wherein s is 0;

t is 0; and

-73-

Y is NH₂;

E is CR⁵ wherein R⁵ is hydrogen or halo; and

G is CR⁵ wherein R⁵ is halo or (C₁-C₆)alkyl;

or when A and B, or E and G, are both CR⁵, the two R⁵ groups may be taken
 5 together with the adjacent carbons to which they are attached to form a (C₅-C₆)cycloalkyl group.

5. A compound according to claim 1, wherein said compound is selected from the group consisting of:

- 1-(4-Chloro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-1-methyl-ethyl)-
 10 benzenesulfonyl]-urea;
- 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;
- 1-(1,2,3,5,6,7-Hexahydro-4-aza-s-indacen-8-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;
- 15 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-thiophene-2-sulfonyl]-urea;
- 1-(4-[1,3]Dioxolan-2-yl-furan-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;
- 1-(2,6-Diisopropyl-phenyl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;
- 20 1-(2,6-Diisopropyl-phenyl)-3-[4-(1-hydroxy-1-methyl-ethyl)-thiophene-2-sulfonyl]-urea;
- 1-(4-Acetyl-thiophene-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;
- 1-(1H-Benzoimidazole-5-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;
- 1-(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-
 25 thiophene-2-sulfonyl]-urea;
- 1-(8-Chloro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonyl]-urea;
- 1-(4-Acetyl-furan-2-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;
- 1-(8-Fluoro-1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[4-(1-hydroxy-1-methyl-ethyl)-
 30 furan-2-sulfonyl]-urea;
- 1-(4-Fluoro-2,6-diisopropyl-phenyl)-3-[3-(1-hydroxy-1-methyl-ethyl)-benzenesulfonyl]-urea;

-74-

1-(6-Fluoro-1H-benzoimidazole-5-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-urea;

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-(1H-indole-6-sulfonyl)-urea;

1-(4-Chloro-2,6-diisopropyl-phenyl)-3-(5-fluoro-1H-indole-6-sulfonyl)-urea;

5 1-[1,2,3,5,6,7-Hexahydro-s-indacen-u-yl)-3-(1H-indole-6-sulfonyl)-urea;

1-(5-Fluoro-1H-indole-6-sulfonyl)-3-(1,2,3,5,6,7-hexahydro-5-indacen-4-yl)-urea;

1-[4-Chloro-2,6-diisopropyl-phenyl]-3-[2-fluoro-5-(2-methyl-(1,3)dioxolan-2-yl)-benzenesulfonyl]-urea;

3-[3-[4-Chloro-2,6-diisopropyl-phenyl]-ureidosulfonyl]-N-methyl-
10 benzenesulfonamide;

1-[2-Fluoro-5-(2-methyl-(1,3)dioxolan-2-yl)benzenesulfonyl]-3-1,2,3,5,6,7-hexahydro-indacen-4-yl)-urea; and

3-[3-(1,2,3,5,6,7-Hexahydro-S-indacen-4-yl)-ureidosulfonyl]-N-methyl-benzenesulfonamide.

15 6. A pharmaceutical composition for the treatment of meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft
20 rejection, and graft-versus-host disease, auto-immune diseases including Type 1 diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation, tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzheimers disease, percussion injury, depression, atherosclerosis and osteoporosis in a mammal, including a human, comprising
25 administering an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in such treatments or inhibition and a pharmaceutically acceptable carrier.

7. A method for treating a condition selected from the group consisting of
30 meningitis and salpingitis, septic shock, disseminated intravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation, arthritis, cholangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury, vasculitis, acute and delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type 1

-75-

diabetes mellitus and multiple sclerosis, periodonate diseases, interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, keloid formation, tumors which produce IL-1 as an autocrine growth factor, cachexia, Alzheimers disease, percussion injury, depression, atherosclerosis and osteoporosis in a mammal, including a human, comprising

5 administering to said mammal an amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, effective in treating such a condition.

8. The compound 4-(1-hydroxy-1-methyl-ethyl)-furan-2-sulfonamide.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 97/01603

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C311/54 A61K31/64

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 93 08161 A (WARNER LAMBERT CO) 29 April 1993 see the whole document	1-6
A	WO 92 01684 A (PFIZER) 6 February 1992	1-8

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

29 January 1998

Date of mailing of the international search report

27.02.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Janus, S

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 97/01603

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This international search report has not been established in respect of
-----the following reasons:

Claims Nos.: 1-4, 6-7 (all in part)

because they relate to subject matter not required to be searched by this
Authority, namely:

Claims Nos.: 1-4, 6-7 (all in part)

because they relate to parts of the international application that do not
comply with the prescribed requirements to such an extent that no
meaningful international search can be carried out, specifically:

These claims are so broad that a sensible search is impossible, on both
economical and technical grounds. Guided by the spirit of the invention
as disclosed especially in the examples, the search was limited to
compounds wherein R2 is either a 2,6-diisopropylbenzene possibly
substituted at the 4-position or a 1,2,3,5,6,7-hexahydro-indacen-4-yl
possibly substituted at the 8-position.

Remark : Although claim 7 is directed to a method of treatment of the
human/animal body , the search has been carried out and based on the
alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. .tional Application No

PCT/IB 97/01603

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9308161 A	29-04-93	US 5254589 A AU 2869792 A MX 9205893 A PT 100960 A	19-10-93 21-05-93 01-04-93 30-11-93
WO 9201684 A	06-02-92	US 5064851 A AT 141601 T CA 2086432 A DE 69121571 D DE 69121571 T EP 0540614 A ES 2090345 T JP 2504659 B JP 5504773 T	12-11-91 15-09-96 25-01-92 26-09-96 09-01-97 12-05-93 16-10-96 05-06-96 22-07-93